{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, io"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "samplepath = \"../../convertedfiles/31016_PromaCareTM_BR.txt\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.path.exists(samplepath)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "#if fs: fs.close()\n",
    "fs = open(samplepath)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['ÿPromaCareTM BR\\n',\n",
       " '    Trade Name:                PromaCareTM BR\\n',\n",
       " '    Catalog Number:            31016\\n',\n",
       " '    INCI Name:                 4-Butylresorcinol\\n',\n",
       " '    CAS Number:                18979-61-8\\n',\n",
       " '    Dosage:                    0.5-1%\\n',\n",
       " '    Properties/Character:      Powder\\n',\n",
       " '                               Oil soluble\\n',\n",
       " '    Application:               Strong inhibitor of tyrosinase and peroxide enzyme;\\n',\n",
       " '                               Perfect skin whitening agent;\\n',\n",
       " '                               A whitening agent of dark skin.\\n',\n",
       " 'UNIPROMA CHEMICAL CO., LIMITED\\n',\n",
       " 'Tel:  +86 21 3925 4391, 3925 4392;\\n',\n",
       " '      +86 21 3925 4393, 3925 4396;\\n',\n",
       " 'Fax: +86 21 3925 4397;\\n',\n",
       " 'Email: info@uniproma.com\\n',\n",
       " 'W eb : www.uniproma.com\\n',\n",
       " ' Uniproma                                                                          Your True Partner for Sun Care TM\\n',\n",
       " '\\n']"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fs.seek(0)\n",
    "fs.readlines()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "fs.seek(0)\n",
    "lines = fs.readlines() "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def getDocProperties(lines):\n",
    "    docProperties = {\"longestsent\" : 0}\n",
    "    lineproperties = {}\n",
    "    for line in lines:\n",
    "        if line:\n",
    "            linemeta = lineproperties.get(line)\n",
    "            if not linemeta:\n",
    "                linemeta = {}\n",
    "                lineproperties[line] = linemeta\n",
    "            if line[0] != ' ':\n",
    "                linemeta['startcol'] = 0\n",
    "            else:\n",
    "                for i, c in enumerate(line):\n",
    "                    if c != ' ':\n",
    "                        linemeta['startcol'] = i\n",
    "                        break\n",
    "            linemeta['fulllength'] = len(line)\n",
    "            linemeta['actuallenght'] = len(line.strip())\n",
    "\n",
    "            longestsent = docProperties.get(\"longestsent\")\n",
    "            l = longestsent\n",
    "            l = max(l, len(line))\n",
    "            docProperties[\"longestsent\"] = l\n",
    "    return (lineproperties, docProperties)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "({'ÿPromaCareTM BR\\n': {'startcol': 0, 'fulllength': 16, 'actuallenght': 15},\n",
       "  '    Trade Name:                PromaCareTM BR\\n': {'startcol': 4,\n",
       "   'fulllength': 46,\n",
       "   'actuallenght': 41},\n",
       "  '    Catalog Number:            31016\\n': {'startcol': 4,\n",
       "   'fulllength': 37,\n",
       "   'actuallenght': 32},\n",
       "  '    INCI Name:                 4-Butylresorcinol\\n': {'startcol': 4,\n",
       "   'fulllength': 49,\n",
       "   'actuallenght': 44},\n",
       "  '    CAS Number:                18979-61-8\\n': {'startcol': 4,\n",
       "   'fulllength': 42,\n",
       "   'actuallenght': 37},\n",
       "  '    Dosage:                    0.5-1%\\n': {'startcol': 4,\n",
       "   'fulllength': 38,\n",
       "   'actuallenght': 33},\n",
       "  '    Properties/Character:      Powder\\n': {'startcol': 4,\n",
       "   'fulllength': 38,\n",
       "   'actuallenght': 33},\n",
       "  '                               Oil soluble\\n': {'startcol': 31,\n",
       "   'fulllength': 43,\n",
       "   'actuallenght': 11},\n",
       "  '    Application:               Strong inhibitor of tyrosinase and peroxide enzyme;\\n': {'startcol': 4,\n",
       "   'fulllength': 83,\n",
       "   'actuallenght': 78},\n",
       "  '                               Perfect skin whitening agent;\\n': {'startcol': 31,\n",
       "   'fulllength': 61,\n",
       "   'actuallenght': 29},\n",
       "  '                               A whitening agent of dark skin.\\n': {'startcol': 31,\n",
       "   'fulllength': 63,\n",
       "   'actuallenght': 31},\n",
       "  'UNIPROMA CHEMICAL CO., LIMITED\\n': {'startcol': 0,\n",
       "   'fulllength': 31,\n",
       "   'actuallenght': 30},\n",
       "  'Tel:  +86 21 3925 4391, 3925 4392;\\n': {'startcol': 0,\n",
       "   'fulllength': 35,\n",
       "   'actuallenght': 34},\n",
       "  '      +86 21 3925 4393, 3925 4396;\\n': {'startcol': 6,\n",
       "   'fulllength': 35,\n",
       "   'actuallenght': 28},\n",
       "  'Fax: +86 21 3925 4397;\\n': {'startcol': 0,\n",
       "   'fulllength': 23,\n",
       "   'actuallenght': 22},\n",
       "  'Email: info@uniproma.com\\n': {'startcol': 0,\n",
       "   'fulllength': 25,\n",
       "   'actuallenght': 24},\n",
       "  'W eb : www.uniproma.com\\n': {'startcol': 0,\n",
       "   'fulllength': 24,\n",
       "   'actuallenght': 23},\n",
       "  ' Uniproma                                                                          Your True Partner for Sun Care TM\\n': {'startcol': 1,\n",
       "   'fulllength': 117,\n",
       "   'actuallenght': 115},\n",
       "  '\\n': {'startcol': 0, 'fulllength': 1, 'actuallenght': 0}},\n",
       " {'longestsent': 117})"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "getDocProperties(lines)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "samplepath1 = \"../../convertedfiles/DermaPep A440 Brochure.txt\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "fs1 = open(samplepath1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fs1.seek(0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'ÿExperience The Magic of Science\\n                              DermaPep\" A440\\n                              Innovative Anti-Aging Tetrapeptide\\n                                                                  Represented in the USA by\\n                                                                  TRI-K Industries, Inc.\\n                                                                  Tel: (973) 298-8850\\n                                                                  Fax: (973) 298-8940\\n                                                                  www.tri-k.com info@tri-k.com\\n                                  DermaPep\\n                                  Experience the magic of science\\n\\nÿl Anti-aging\\n   DermaPep\" A350\\n   DermaPep\" A420\\n   DermaPep\" A440\\n   DermaPep\" A530\\nl Whitening\\n   DermaPep\" A350\\n   DermaPep\" UL\\n   DermaPep\" W220\\n   DermaPep\" W411\\nl Anti-inflammatory\\n   DermaPep\" A350\\n   DermaPep\" A440\\n   DermaPep\" A530\\n   DermaPep\" UL\\n   DermaPep\" W220\\n   DermaPep\" W411\\n\\nÿDermaPep\" A440\\nAnti-Aging Peptide\\nIntroduction                                                  Function\\nCollagen represents the main component of the                 l Anti-wrinkle effect for face and body\\nextracellular matrix of the dermal connective tissue and      l Reduction of MMP1 synthesis\\n                                                              l Restoration of procollagen type 1\\nits concentration decreases as we age. It is known that\\n                                                              l Providing exceptional anti-aging benefits\\nthe loss of collagen, especially in photoaged skin, is not\\n                                                              l Anti-aging effect against environmental stimulus\\nonly due to a reduction of the synthesis but also due to\\nits enhanced degradation. The enzyme mainly                      such as UV irradiation\\nresponsible for collagen breakdown and inhibition of          Applications\\nnew collagen formation in the skin is MMP-1 which\\ncleaves collagen type I, III, VII, VIII. Exposure of the skin DermaPep\" A440 can be incorporated in cosmetic\\nto UV radiation results in the upregulation of several        formulations such as emulsions, oily sera, gels and\\ndifferent MMPs and the repeated upregulation of these         creams for anti-aging and anti-wrinkle purpose.\\ncollagen-degrading enzymes over time is thought to\\nunderlie the collagen damage that is one of the               Formulation\\nhallmarks of photoaging.                                      l Dermatological tolerance : Standard testing has been\\n                                                                performed on DermaPep\" A440 which has showed\\nIn a healthy skin, the synthesis and degradation of the         neither cytotoxic effects nor any irritation or\\nmatrix are well in balance. However, this intricate             sensitization reaction in healthy volunteers with an\\nbalance gets disrupted as we age, in which too little of        occlusive single patch test.\\nthe matrix is synthesized and too much is degraded.           l Recommended concentration : 1-3 %\\nMany of well-known skin aging treatments are aimed at\\nreplenishing skin matrix by stimulating the synthesis of      Product Information\\nthe matrix. Unfortunately, this approach fails in some        l Appearance : Transparent solution\\npeople, especially old people, whose ability to respond       l INCI/CTFA-Declaration : Myristoyl Tetrapeptide-34\\nto matrix synthesis boosters is considerably declined.          (and) Butylene Glycol\\n                                                              l Active ingredient content\\nDermaPepTM A440, innovative antiaging tetrapeptide,            : 0.15% Myristoyl Tetrapeptide-34\\nhas been developed to maximally and effectively inhibit       l Powder purity : 95 % up\\nthese matrix degrading MMPs and to restore collagen-          l Preservative : None\\nlevels back to normal. In vitro results show that\\nDermaPepTM A440 greatly inhibited the expression and\\nproduction of MMP-1 under both UV-stimulated and\\nnon-stimulated condition and restored collagen levels\\nsignificantly. In addition, DermaPepTM A440\\nconsiderably lowered the MMP levels that have been\\nproduced by ROS or RNS. Finally, in vivo clinical study\\nresults prove that DermaPepTM A440 is surely one of\\nthe best antiaging agents in the market.\\n\\nÿ              DermaPep\" A440\\n              Safety\\n              Cell Cytotoxicity Test                                             Skin Irritation Test\\n              Hs68 cells were seeded into 96-well plates (2 x 103) and           Skin irritation test was performed on 31 healthy Asian\\n              treated with different concentrations of Myristoyl                 volunteers (Spincontrol Asia (study report number IR-\\n              Tetrapeptide-34 for 24 hours. Cell viability was                   6Q01-MW-DE08), Bangkok, Thailand).\\n              assessed by MTT assay and was shown relative to\\n              untreated control. Absorbance was measured by an                   Evaluation and grading of skin irritation\\n                                                                                 l Erythema (no redness = 0 to very strong redness=5)\\n              ELISA reader at 540 nm.\\n                                                                                   After 24 hrs, mean score = 0.00 (max = 0)\\n                                                                                   After 48 hrs, mean score = 0.00 (max = 0)\\n                                                                                 l Oedema (no oedema = 0 to very strong oedema =5)\\n                                                                                   After 24 hrs, mean score = 0.00 (max = 0)\\n                                                                                   After 48 hrs, mean score = 0.00 (max = 0)\\n                                                                                 l Scaling (no scaling = 0 to very strong scaling = 5)\\n                                                                                   After 24 hrs, mean score = 0.00 (max = 0)\\n                                                                                   After 48 hrs, mean score = 0.00 (max = 0)\\n                                                                                 Mutagenicity (Ames Test)\\n                                                                                 Myristoyl tetrapeptide-34 at 5 different concentrations\\n                                                                                 (30,60,90,180, 360 ppm) were evaluated to predict its\\n                                                                                 potential to cause mutagenicity. Five different\\n                                                                                 auxotrophic mutants were used to assesse directly or in\\n                                                                                 the presence of liver S9 fractions.\\n              MTT Assay\\n                                                                                 No mutagenicity was observed.\\n                                120\\n                                                                                 In vitro Ocular Irritation Test\\n                                      100          97         100      98        DermaPep\" A440 at 3 different concentrations (2, 4,\\n                                100         94           95                 95\\nCell viability (% of control)\\n                                                                                 8 %) and butylene glycol were evaluated with the\\n                                80                                               ocular irritection assay system (CA, USA).\\n                                60                                               The ocular results demonstrated that the DermaPepTM\\n                                                                                 A440 was classified as mild irritants.\\n                                40\\n                                20\\n                                 0\\n                                      0     2      5     10    17      25   30\\n                                                 Concentration (ppm)\\n\\nÿ DermaPep\" A440\\n In vitro efficacy\\n Inhibition of MMP-1 Production\\n                                                                                       Inhibition of MMP-1 Production\\n Hs68 cells were seeded into 6-well plates and treated\\n with TGF-b, retinoic acid or Myristoyl Tetrapeptide-34\\n followed by UV radiation or not for 48 hours. Equal                                                 120\\n                                                                                                           100                     - 82 %\\n amounts of media were analyzed by ELISA assay for                                                   100\\n                                                                                   MMP1 production\\n MMP-I. Cell viability was used for sample\\n                                                                                                      80                     71\\n standardization.\\n                                                                                                      60\\n                                                                                    (% of control)\\n Myristoyl Tetrapeptide-34 significantly decreased\\n                                                                                                      40\\n MMP-1 production.                                                                                                      24\\n                                                                                                                                    18\\n                                                                                                      20          15                        12\\n                                                                                           0\\n                                                                                  TGF-²1         -               0.01   -     -      -       -     (ppm)\\n                                                                                  Retinoic acid -                  -    1     -      -       -\\n                                                                                  Myristoyl\\n                                                                                                 -                -     -    5      10      20\\n                                                                                  Tetrapeptide-34\\nInhibition of MMP-1 production after UVA or UVB irradiation\\n                                 336                      - 128 %\\n                     350                                                                             250\\n                                                                                                                 208                     - 137 %\\n                     300\\n   MMP1 production                                                                 MMP1 production\\n                                                                                                     200\\n                     250\\n                     200                    160 167                                                  150\\n                                                                                                                             107\\n    (% of control)\\n                                                                                                           100          98\\n                                                                                    (% of control)\\n                     150                                                                                                            95\\n                           100         98             92                                             100\\n                     100                                                                                                                    59\\n                      50                                    32   21     34                            50\\n                      0                                                                               0\\n  UVA 30J/cm2 -                  +       + +     +    +      +      +   + (ppm)\\n                                                                                  UVB 80mJ/cm2 -                  +     +     +      +      +      (ppm)\\n  TGF-²1        -                      0.01      -    -      -      -   -\\n                                                                                  Retinoic acid   -                     1     -      -      -\\n  Retinoic acid -                           1    -    -      -      -   -\\n                                                                                  Myristoyl\\n  Myristoyl                                                                                       -                           5     10      20\\n                -                                2    5     10 20 30              Tetrapeptide-34\\n  Tetrapeptide-34\\n\\nÿDermaPep\" A440\\nIn vitro efficacy\\nEffect on Procollagen 1 Production                                 Changes in MMP-1 and ECM gene expression\\nHs68 cells were seeded into 6-well plates and treated              Hs68 cells were seeded into 6-well plates and treated\\nwith retinoic acid or Myristoyl Tetrapeptide-34                    with TGF-b, retinoic acid or Myristoyl terapeptide-34\\nfollowed by 30J/cm2 UVA. After 48 hours equal                      followed by 30J/cm2 UVA. After 48 hours, total cellular\\namounts of cell lysates were subjected to                          RNA was extracted and reverse-transcription PCR was\\nelectrophoresis and analyzed by western blot for                   performed to determine MMP-1, procollagen 1,\\nprocollagen type I.                                                fibronectin. GAPDH mRNA level was used for sample\\n                                                                   standardization.\\nMyristoyl Tetrapeptide-34 significantly stimulated the\\nproduction of type I procollagen.                                  Myristoyl Tetrapeptide-34 significantly inhibited UVA\\n                                                                   stimulated MMP-1 expression and stimulated the\\n                                                                   procollagen-1 and fibronectin expression.\\nStimulation of Procollagen I Production                               Changes in MMP-1 and ECM gene expression\\n                               UVA irradiation\\n                                                                                              UVA 30J/cm2\\n                                              Myr                                                   Myr-Tetrapeptide-34\\n                          NT      R.A    Tetrapeptide-34\\n                                                                              NT   UVA TGF- R.A     2       5   10    20 (ppm)\\n                                                                                        b1\\n Procollagen-1\\n                                                              MMP-1\\n ²-actin                                                      Procollagen-1\\n                  4                                           Fibronectin\\n Procollagen I\\n                                                              GAPDH\\n                  3                            2.43\\n (% of control)\\n                  2\\n                      1         1.14\\n                  1\\n                  0\\n      UVA 30J/cm2 +              +               +    (ppm)\\n      Retinoic acid              1         -\\n      Myristoyl\\n                                                 10\\n      Tetrapeptide-34\\n\\nÿ    DermaPep\" A440\\n    In vitro efficacy\\n    Comparison with Retinoids\\n    Hs68 cells were seeded into 6-well plates and then\\n    treated with retinyl palmitate, Myristoyl tetrapeptide-\\n    34 or both (left figure) or retinol, Myristoyl\\n    Tetrapeptide-34 or both(right figure) followed by\\n    30J/cm2 UVA . Equal amounts of media were analyzed\\n    by ELISA assay for MMP-I. Cell viability was used for\\n    sample standardization\\n    Myristoyl Tetrapeptide-34 showed greater effect on\\n    reducing MMP-1 than retinyl palmitate or retinol alone.\\n    In addition, there was no synergy between retinyl\\n    palmitate and Myristoyl Tetrapeptide-34 or retinol and\\n    Myristoyl Tetrapeptide-34, respectively.\\n     Comparison with Retinyl Palmitate                                                     Comparison with Retinol on MMP-1 Inhibition\\n     on MMP-1 Inhibition\\n                                    339                                                                                  327\\n                        350                                                                                  350\\n                                               298                                                                                   291\\n                        300                                                                                  300\\n                                                          252\\n      MMP1 production                                                                      MMP1 production\\n                        250                                                                                  250\\n                                                                     207                                                       195\\n                        200                                                                                  200\\n                        150                                                                                  150\\n       (% of control)                                                                       (% of control)\\n                              100                                                                                  100                     112   101\\n                                          97\\n                        100                          71                                                      100\\n                                                                46         45     47\\n                         50                                                                                   50\\n                         0                                                                                    0\\nUVA 30J/cm2                    -    +     +     +    +     +    +     +    +      +     UVA 30J/cm2       -       +             +     +     +     +\\nRetinoic acid                             1                                             Retinoic acid                           1    -     -      -\\nRetinyl palmitate                              10    10   20 20      25 25        -     Retinol                                 -    5     5      -\\nMyristoyl Tetrapeptide-34                 -     -    10    -    10    -    10     10    Myristoyl Tetrapeptide-34               -     -    10     10\\n                                                                                (ppm)                                                            (ppm)\\n\\nÿDermaPep\" A440\\nIn vitro efficacy\\nSignaling of MMP-1 expression\\n                                                             AP-1 component gene expression(PCR)\\nHs68 cells were seeded into 6-well plates and\\npretreated with the retinoic acid or Myristoyl\\nTetrapeptide-34 for 24 and then stimulated by UV                           c-fos\\nirradiation. After 30 minutes, total cellular RNA was\\n                                                                           c-jun\\nextracted and reverse-transcription PCR was performed\\nto determine c-jun and c-fos mRNA level. b-actin was                       GAPDH\\nused for sample standardization.\\n                                                                 UV                         -         +            +        +     +\\nMyristoyl Tetrapeptide-34 significantly decreased UVB            Myristoyl Tetrapeptide-34                         5        10   20 (ppm)\\ninduced c-fos mRNA expression\\n Mechanism of MMP-1 expression                               c-fos/c-Jun gene expression\\n                                                                                            125\\n                                                                           120                  110        108                    108\\n                                                                                                                        107\\n                                                                                      100\\n                                                             mRNA expression\\n                                                                                    100\\n                                                                           100                                                            c-fos\\n                                                                                                                                          c-jun\\n                                                                               80\\n                                                              (% of control)\\n                                                                                                          61\\n                                                                               60                                      55\\n                                                                                                                                 41\\n                                                                               40\\n                                                                               20\\n                                                        UV                            -         +          +                +         +\\n                                                        Myristoyl Tetrapeptide-34                              5        10        20 (ppm)\\n\\nÿDermaPep\" A440\\nIn vitro efficacy\\nInhibition of ROS Induced MMP-1\\nProduction and AP-1 Signaling\\nHs68 cells were seeded into 6-well plates and treated\\nwith Myristoyl Tetrapeptide-34 followed by or H2O2.\\nEqual amounts of media were analyzed by ELISA assay\\nfor MMP-I. Cell viability was used for sample\\nstandardization. For AP-1 signaling, total cellular RNA\\nwas extracted and reverse-transcription PCR was\\nperformed to determine c-jun and c-fos mRNA level.\\nGAPDH was used for sample standardization.\\nMyristoyl Tetrapeptide-34 significantly decreased ROS\\nradical stimulated MMP-1 production and c-fos mRNA\\nexpression.\\n   Inhibition of MMP-1 production against                        AP-1 component gene expression(PCR)\\n   H2O2\\n                                                                              c-fos\\n                                                                              c-jun\\n                                 153        - 149 %\\n                     150                                                      GAPDH\\n   MMP1 production\\n                                                                                                 208\\n                           100                                                 200\\n                     100               88\\n                                                                 mRNA expression\\n                                              74\\n    (% of control)\\n                                                                                   150\\n                                                                                                  119    118    115    120\\n                     50                                                                    100\\n                                                                                         100                                 c-fos\\n                                                                  (% of control)\\n                                                                               100                      77            84     c-jun\\n                                                                                                               75\\n                      0\\n                                                                                   50\\n  H2O2 (500uM) -                 +     +       +      (ppm)\\n  Myristoyl\\n                  -                    5      10                        0\\n  Tetrapeptide-34                                             H2O2 (500uM)                 -       +     +      +     +\\n                                                              Myristoyl Tetrapeptide-34                  5     10     20 (ppm)\\n\\nÿDermaPep\" A440\\nIn vitro efficacy\\nInhibition of RNS Induced MMP-1\\nProduction and AP-1 Signaling\\nHs68 cells were seeded into 6-well plates and treated\\nwith the Myristoyl Tetrapeptide-34 followed by\\nSNAP(S-nitroso-N-acetylpenicillamine. Equal amounts\\nof media were analyzed by ELISA assay for MMP-I. Cell\\nviability was used for sample standardization. For AP-1\\nsignaling, total cellular RNA was extracted and reverse-\\ntranscription PCR was performed to determine c-jun\\nand c-fos mRNA level. GAPDH was used for sample\\nstandardization.\\nMyristoyl Tetrapeptide-34 significantly decreased RNS\\nradical stimulated MMP-1 production and c-fos mRNA\\nexpression.\\n Inhibition of MMP-1 production against                          AP-1 component gene expression(PCR)\\n SNAP\\n                                                                          c-fos\\n                                                                          c-jun\\n                                185         - 115 %\\n                                                                          GAPDH\\n  MMP1 production\\n                                                                           140\\n                    150\\n                                                                                                127\\n                                      111                                                                             120\\n                                                                                                 119\\n                                                                 mRNA expression\\n                          100                                                                           118    115\\n                    100                       87                               120\\n   (% of control)                                                                         100\\n                                                                                        100\\n                    50                                                         100                                           c-fos\\n                                                                  (% of control)\\n                                                                                                                     84      c-jun\\n                     0                                                                                 77     75\\n                                                                                   80\\n SNAP(500uM) -                  +     +        +      (ppm)\\n Myristoyl                                                            60\\n                 -                     5      10\\n Tetrapeptide-34\\n                                                              SNAP(100uM)                 -       +     +      +      +\\n                                                              Myristoyl Tetrapeptide-34                 5      10     20 (ppm)\\n\\nÿ DermaPep\" A440\\n In vitro efficacy\\n Anti-inflammatory Effects of Myristoyl                      Anti-inflammatory Effects of Myristoyl\\n Tetrapeptide-34 on Human Fibroblasts                        Tetrapeptide-34 on Keratinocytes\\n Hs68 cells were seeded into 6-well plates and               Human keratinocyte HaCaT cells were treated with\\n pretreated with TGF-b, retinoic acid or Myristoyl           Myristoyl Tetrapeptide-34 and then stimulated with\\n Tetrapeptide-34 followed by 30J/cm2 UVA . After 24          UVB (100 mJ/cm2). After 24 hours, total cellular RNA\\n hours, total cellular RNA was extracted and reverse-        was extracted and reverse-transcription PCR was\\n transcription PCR was performed to determine IL-1²,         performed to determine IL-1a, IL-1², IL-6. GAPDH\\n IL-6, IL-8 . GAPDH mRNA level was used for sample           mRNA level was used for sample standardization.\\n standardization.                                            Myristoyl Tetrapeptide-34 significantly inhibited UVB-\\n Myristoyl Tetrapeptide-34 greatly inhibited UVA-            induced expression of pro-inflammatory cytokines in\\n induced expression of pro-inflammatory cytokines in         human keratinocytes.\\n human skin fibroblasts.\\n  Pro-inflammatory cytokines Level (Hs68)                    Pro-inflammatory cytokines Level (HaCaT)\\n                                                                                              UVB\\n                            UVA 30J/cm2                                                    Myr-Tetrapeptide-34\\n                                                                                 NT              1    5     (ppm)\\n                                  Myr-Tetrapeptide-34\\n          NT    UVA TGF- R.A       2     5    10    20 (ppm)           IL-1±\\n                        b1\\nIL-1b                                                                  IL-1²\\nIL-6\\n                                                                       IL-6\\nIL-8\\n                                                                       IL-8\\nGAPDH\\n                                                                       GAPDH\\n\\nÿDermaPep\" A440\\nIn vitro efficacy\\nDNA Chip Assay\\nCHIP data of pro-inflammatory related gene\\n                                                                                                        Gene       Genbank                   A440/UV\\n  Index      ProbeName                                     Description                                                        UniGeneID\\n                                                                                                       Symbol      Accession                 intensity\\n                          tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), trans\\n     1078 A_23_P121253                                                                              TNFSF10      NM_003810    Hs.478275     0.712051591\\n                          cript variant 1, mRNA\\n                          tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B), tra\\n     2139 A_23_P14174                                                                               TNFSF13B     NM_006573    Hs.525157     0.444733865\\n                          nscript variant 1, mRNA\\n     7521 A_23_P376488    tumor necrosis factor (TNF), mRNA                                         TNF          NM_000594    Hs.241570     0.679159864\\n     3365 A_23_P165624    tumor necrosis   factor, alpha-induced protein 6 (TNFAIP6), mRNA          TNFAIP6      NM_007115    Hs.437322     0.542426693\\n                          tumor necrosis   factor receptor superfamily, member 11b (TNFRSF11B),\\n    10479 A_23_P71530                                                                               TNFRSF11B NM_002546       Hs.81791       0.50666134\\n                          mRNA\\n                          tumor necrosis   factor receptor superfamily, member 6b, decoy (TNFRSF\\n     4776 A_23_P218646                                                                              TNFRSF6B     NM_003823    Hs.434878     0.587013243\\n                          6B), mRNA\\n                          tumor necrosis   factor receptor superfamily, member 6b, decoy (TNFRSF\\n    25168 A_33_P3305571                                                                             TNFRSF6B     NM_003823    Hs.434878     0.589897775\\n                          6B), mRNA\\n     1337 A_23_P126836    tumor necrosis   factor (ligand) superfamily, member 4 (TNFSF4), mRNA     TNFSF4       NM_003326    Hs.181097     0.858187786\\n    21238 A_33_P3246833   interleukin 1 receptor antagonist (IL1RN), transcript variant 4, mRNA     IL1RN        NM_173843    Hs.81134      0.398674612\\n    12985 A_24_P200023    interleukin 1 receptor, type I (IL1R1), mRNA                              IL1R1        NM_000877    Hs.701982     0.547208757\\n    31154 A_33_P3396389   interleukin 1 receptor, type I (IL1R1), mRNA                              IL1R1        NM_000877    Hs.701982     0.654729398\\n                          interleukin 1 receptor-associated kinase 1 (IRAK1), transcript variant 1,\\n    10576 A_23_P73780                                                                               IRAK1        NM_001569    Hs.522819     0.826588326\\n                          mRNA\\n    11156 A_23_P85209     interleukin 13 receptor, alpha 2 (IL13RA2), mRNA                          IL13RA2      NM_000640    Hs.336046     0.454015552\\n     1964 A_23_P138680    interleukin 15 receptor, alpha (IL15RA), transcript variant 2, mRNA       IL15RA       NM_172200    Hs.524117     0.696403722\\n                          peroxisome proliferator-activated receptor gamma (PPARG), transcript v\\n     5072 A_23_P252062                                                                              PPARG        NM_138711    Hs.162646     0.620602594\\n                          ariant 3, mRNA\\n                          peroxisome proliferator-activated receptor gamma (PPARG), transcript v\\n    28110 A_33_P3350726                                                                             PPARG        NM_138711    Hs.162646     0.587618207\\n                          ariant 3, mRNA\\nCHIP data of ECM protein related gene\\n                                                                                                Gene     Genbank                   UV/NT        A440/UV\\n Index      ProbeName                                  Description                                                  UniGeneID\\n                                                                                               Symbol    Accession                intensity     intensity\\n   25105 A_33_P3304668  collagen, type I, alpha 1 (COL1A1), mRNA                             COL1A1     NM_000088 Hs.172928     0.445770446 1.932809889\\n   11097 A_23_P83818    collagen, type V, alpha 1 (COL5A1), mRNA                             COL5A1     NM_000093 Hs.210283     0.749845964 1.621188441\\n   33475 A_33_P3629678  collagen, type V, alpha 1 (COL5A1), mRNA                             COL5A1     NM_000093 Hs.210283     0.559161349 1.618872875\\n   31278 A_33_P3398236  collagen, type XXVIII, alpha 1                                       COL28A1    AJ890452    Hs.491104   0.934087883 3.457301057\\n   14419 A_24_P334130   fibronectin 1 (FN1), transcript variant 7, mRNA                      FN1        NM_054034 Hs.203717     0.850157729 2.353647741\\n    2910 A_23_P156327   transforming growth factor, beta-induced, 68kDa (TGFBI), mRNA TGFBI             NM_000358 Hs.369397     0.682829566 2.148446928\\n   25707 A_33_P3313825  transforming growth factor, beta receptor II (70/80kDa)              TGFBR2     AJ786388    Hs.82028                    1.62420191\\n                        transforming growth factor, beta 2 (TGFB2), transcript variant 2,\\n   15179 A_24_P402438                                                                        TGFB2      NM_003238 Hs.133379     0.971181556     1.69905287\\n                        mRNA\\n                        latent transforming growth factor beta binding protein 2 (LTBP2)\\n    8176 A_23_P405129                                                                        LTBP2      NM_000428 Hs.512776     1.024822695     2.42692819\\n                        , mRNA\\n    3781 A_23_P19663    connective tissue growth factor (CTGF), mRNA                         CTGF       NM_001901 Hs.410037     0.332717584 3.151554741\\n   30141 A_33_P3380797  fibroblast growth factor 3 (FGF3), mRNA                              FGF3       NM_005247 Hs.37092      0.965838192 2.016988657\\n    3838 A_23_P200741   dermatopontin (DPT), mRNA [NM_001937]                                DPT        NM_001937 Hs.80552      0.762254902 1.327178047\\n                        signal transducer and activator of transcription 1, 91kDa (STAT1),\\n   13766 A_24_P274270                                                                        STAT1      NM_139266 Hs.642990     2.028586279 0.346110016\\n                        transcript variant beta, mRNA\\n    9975 A_23_P62115    TIMP metallopeptidase inhibitor 1 (TIMP1), mRNA                      TIMP1      NM_003254 Hs.522632     0.850732951 1.517430948\\n                        matrix metallopeptidase 1 (interstitial collagenase) (MMP1), trans\\n    3547 A_23_P1691                                                                          MMP1       NM_002421 Hs.83169      1.564405238 0.568818868\\n                        cript variant 1, mRNA\\n                        matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3),\\n    3181 A_23_P161698                                                                        MMP3       NM_002422 Hs.375129     2.803817166     0.82164818\\n                        mRNA\\n                        matrix metallopeptidase 14 (membrane-inserted) (MMP14), mRN\\n   16187 A_24_P82106                                                                         MMP14      NM_004995 Hs.2399       1.135234216 0.695241922\\n                        A\\n\\nÿDermaPep\" A440\\nIn vivo efficacy\\nAnti-Aging Efficacy on Asian Skin Type\\n                                                         Anti aging effect\\nIn a clinical study with 21 Asian healthy female\\n                                                                                                                                     Control\\nvolunteers (Korea), aged 30 to 65, 2 % formula                                                                                       DermaPepTM A440\\ncontaining DermaPep\"A440 had been applied twice                                                        R1      R2      R3     R4        R5       R6\\n                                                         Variation of the reduction rate(%)\\n                                                                                                 0\\ndaily during 12 weeks on the face area. Evaluation was\\n                                                                                                 -5\\nperformed by Transparancy profilometry analysis using\\n                                                                                                -10\\nvisiometer SV600(Courage-Khazaka electronic GmbH,                                                                             -8                 -8\\n                                                                                                -15                   -11\\nGermany) and digital photography.                                                                     -14                              -15\\n                                                                                                -20\\n                                                                                                              -19\\nDermaPep\"A440 showed significant improvement in                                                 -25                            -22\\nall the parameters measured and proved to be the                                                -30                     -25\\n                                                                                                        -27\\n                                                                                                                -29                      -28\\npowerful anti-wrinkle agent.                                                                    -35\\n                                                                                                -40                                                   -37\\n                                                         R1: Skin roughness\\n                                                         R2: Maximum roughness\\n                                                         R3: Average roughness\\n                                                         R4: Smoothness depth\\n                                                         R5: Arithmetic average roughness\\n                                                         R6: Expert\\x19s assessment\\nIllustrative Picture_Code No.11915-K1-12\\n                                                                                                              2% DERMAPEP\" A440\\nT0                              T0+4Weeks\\n                                                                                                     Code                  T+4          T+8       T+12\\n                                                                                                                     T0\\n                                                                                                 11915-K1-12              weeks        weeks      weeks\\n                                                                                                Skin Roughness      134.2 93.08        99.35      63.18\\n                                                                                              Maxium Roughness      90.13 66.23        68.86      49.11\\n                                                                                              Average Roughness      53   48.03         45.6       35.5\\n                                                                                              Smoothness Depth      62.31 36.36        38.47      26.45\\n                                                                                              Arithmetic average\\n                                                                                                                    31.24 13.62         17.04         9.74\\n                                                                                                  Roughness\\nT0+8Weeks                       T0+16Weeks                                                    Experts assessment      3     3                2          1\\n\\nÿ                                                  Personal Care Ingredients Business Unit\\n                                                  http://www.dermapep.com E-mail : dermapep@mwc.co.kr\\n                                                                                                      Last revised on Apr 17h, 2013\\nMIWON COMMERCIAL CO., LTD. 405-3 MONGRAE-DONG, DANWON-GU, ANSAN-SHI, GYEONGGI, 425-100, KOREA PHONE +82-31-8084-8410 FAX +82-31-492-2061\\nwww.dermapep.com, www.mwc.com\\n\\n'"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fs1.read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fs1.seek(0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "({'ÿExperience The Magic of Science\\n': {'startcol': 0,\n",
       "   'fulllength': 33,\n",
       "   'actuallenght': 32},\n",
       "  '                              DermaPep\" A440\\n': {'startcol': 30,\n",
       "   'fulllength': 45,\n",
       "   'actuallenght': 14},\n",
       "  '                              Innovative Anti-Aging Tetrapeptide\\n': {'startcol': 30,\n",
       "   'fulllength': 65,\n",
       "   'actuallenght': 34},\n",
       "  '                                                                  Represented in the USA by\\n': {'startcol': 66,\n",
       "   'fulllength': 92,\n",
       "   'actuallenght': 25},\n",
       "  '                                                                  TRI-K Industries, Inc.\\n': {'startcol': 66,\n",
       "   'fulllength': 89,\n",
       "   'actuallenght': 22},\n",
       "  '                                                                  Tel: (973) 298-8850\\n': {'startcol': 66,\n",
       "   'fulllength': 86,\n",
       "   'actuallenght': 19},\n",
       "  '                                                                  Fax: (973) 298-8940\\n': {'startcol': 66,\n",
       "   'fulllength': 86,\n",
       "   'actuallenght': 19},\n",
       "  '                                                                  www.tri-k.com info@tri-k.com\\n': {'startcol': 66,\n",
       "   'fulllength': 95,\n",
       "   'actuallenght': 28},\n",
       "  '                                  DermaPep\\n': {'startcol': 34,\n",
       "   'fulllength': 43,\n",
       "   'actuallenght': 8},\n",
       "  '                                  Experience the magic of science\\n': {'startcol': 34,\n",
       "   'fulllength': 66,\n",
       "   'actuallenght': 31},\n",
       "  '\\n': {'startcol': 0, 'fulllength': 1, 'actuallenght': 0},\n",
       "  'ÿl Anti-aging\\n': {'startcol': 0, 'fulllength': 14, 'actuallenght': 13},\n",
       "  '   DermaPep\" A350\\n': {'startcol': 3, 'fulllength': 18, 'actuallenght': 14},\n",
       "  '   DermaPep\" A420\\n': {'startcol': 3, 'fulllength': 18, 'actuallenght': 14},\n",
       "  '   DermaPep\" A440\\n': {'startcol': 3, 'fulllength': 18, 'actuallenght': 14},\n",
       "  '   DermaPep\" A530\\n': {'startcol': 3, 'fulllength': 18, 'actuallenght': 14},\n",
       "  'l Whitening\\n': {'startcol': 0, 'fulllength': 12, 'actuallenght': 11},\n",
       "  '   DermaPep\" UL\\n': {'startcol': 3, 'fulllength': 16, 'actuallenght': 12},\n",
       "  '   DermaPep\" W220\\n': {'startcol': 3, 'fulllength': 18, 'actuallenght': 14},\n",
       "  '   DermaPep\" W411\\n': {'startcol': 3, 'fulllength': 18, 'actuallenght': 14},\n",
       "  'l Anti-inflammatory\\n': {'startcol': 0,\n",
       "   'fulllength': 20,\n",
       "   'actuallenght': 19},\n",
       "  'ÿDermaPep\" A440\\n': {'startcol': 0, 'fulllength': 16, 'actuallenght': 15},\n",
       "  'Anti-Aging Peptide\\n': {'startcol': 0,\n",
       "   'fulllength': 19,\n",
       "   'actuallenght': 18},\n",
       "  'Introduction                                                  Function\\n': {'startcol': 0,\n",
       "   'fulllength': 71,\n",
       "   'actuallenght': 70},\n",
       "  'Collagen represents the main component of the                 l Anti-wrinkle effect for face and body\\n': {'startcol': 0,\n",
       "   'fulllength': 102,\n",
       "   'actuallenght': 101},\n",
       "  'extracellular matrix of the dermal connective tissue and      l Reduction of MMP1 synthesis\\n': {'startcol': 0,\n",
       "   'fulllength': 92,\n",
       "   'actuallenght': 91},\n",
       "  '                                                              l Restoration of procollagen type 1\\n': {'startcol': 62,\n",
       "   'fulllength': 98,\n",
       "   'actuallenght': 35},\n",
       "  'its concentration decreases as we age. It is known that\\n': {'startcol': 0,\n",
       "   'fulllength': 56,\n",
       "   'actuallenght': 55},\n",
       "  '                                                              l Providing exceptional anti-aging benefits\\n': {'startcol': 62,\n",
       "   'fulllength': 106,\n",
       "   'actuallenght': 43},\n",
       "  'the loss of collagen, especially in photoaged skin, is not\\n': {'startcol': 0,\n",
       "   'fulllength': 59,\n",
       "   'actuallenght': 58},\n",
       "  '                                                              l Anti-aging effect against environmental stimulus\\n': {'startcol': 62,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 50},\n",
       "  'only due to a reduction of the synthesis but also due to\\n': {'startcol': 0,\n",
       "   'fulllength': 57,\n",
       "   'actuallenght': 56},\n",
       "  'its enhanced degradation. The enzyme mainly                      such as UV irradiation\\n': {'startcol': 0,\n",
       "   'fulllength': 88,\n",
       "   'actuallenght': 87},\n",
       "  'responsible for collagen breakdown and inhibition of          Applications\\n': {'startcol': 0,\n",
       "   'fulllength': 75,\n",
       "   'actuallenght': 74},\n",
       "  'new collagen formation in the skin is MMP-1 which\\n': {'startcol': 0,\n",
       "   'fulllength': 50,\n",
       "   'actuallenght': 49},\n",
       "  'cleaves collagen type I, III, VII, VIII. Exposure of the skin DermaPep\" A440 can be incorporated in cosmetic\\n': {'startcol': 0,\n",
       "   'fulllength': 109,\n",
       "   'actuallenght': 108},\n",
       "  'to UV radiation results in the upregulation of several        formulations such as emulsions, oily sera, gels and\\n': {'startcol': 0,\n",
       "   'fulllength': 114,\n",
       "   'actuallenght': 113},\n",
       "  'different MMPs and the repeated upregulation of these         creams for anti-aging and anti-wrinkle purpose.\\n': {'startcol': 0,\n",
       "   'fulllength': 110,\n",
       "   'actuallenght': 109},\n",
       "  'collagen-degrading enzymes over time is thought to\\n': {'startcol': 0,\n",
       "   'fulllength': 51,\n",
       "   'actuallenght': 50},\n",
       "  'underlie the collagen damage that is one of the               Formulation\\n': {'startcol': 0,\n",
       "   'fulllength': 74,\n",
       "   'actuallenght': 73},\n",
       "  'hallmarks of photoaging.                                      l Dermatological tolerance : Standard testing has been\\n': {'startcol': 0,\n",
       "   'fulllength': 117,\n",
       "   'actuallenght': 116},\n",
       "  '                                                                performed on DermaPep\" A440 which has showed\\n': {'startcol': 64,\n",
       "   'fulllength': 109,\n",
       "   'actuallenght': 44},\n",
       "  'In a healthy skin, the synthesis and degradation of the         neither cytotoxic effects nor any irritation or\\n': {'startcol': 0,\n",
       "   'fulllength': 112,\n",
       "   'actuallenght': 111},\n",
       "  'matrix are well in balance. However, this intricate             sensitization reaction in healthy volunteers with an\\n': {'startcol': 0,\n",
       "   'fulllength': 117,\n",
       "   'actuallenght': 116},\n",
       "  'balance gets disrupted as we age, in which too little of        occlusive single patch test.\\n': {'startcol': 0,\n",
       "   'fulllength': 93,\n",
       "   'actuallenght': 92},\n",
       "  'the matrix is synthesized and too much is degraded.           l Recommended concentration : 1-3 %\\n': {'startcol': 0,\n",
       "   'fulllength': 98,\n",
       "   'actuallenght': 97},\n",
       "  'Many of well-known skin aging treatments are aimed at\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  'replenishing skin matrix by stimulating the synthesis of      Product Information\\n': {'startcol': 0,\n",
       "   'fulllength': 82,\n",
       "   'actuallenght': 81},\n",
       "  'the matrix. Unfortunately, this approach fails in some        l Appearance : Transparent solution\\n': {'startcol': 0,\n",
       "   'fulllength': 98,\n",
       "   'actuallenght': 97},\n",
       "  'people, especially old people, whose ability to respond       l INCI/CTFA-Declaration : Myristoyl Tetrapeptide-34\\n': {'startcol': 0,\n",
       "   'fulllength': 114,\n",
       "   'actuallenght': 113},\n",
       "  'to matrix synthesis boosters is considerably declined.          (and) Butylene Glycol\\n': {'startcol': 0,\n",
       "   'fulllength': 86,\n",
       "   'actuallenght': 85},\n",
       "  '                                                              l Active ingredient content\\n': {'startcol': 62,\n",
       "   'fulllength': 90,\n",
       "   'actuallenght': 27},\n",
       "  'DermaPepTM A440, innovative antiaging tetrapeptide,            : 0.15% Myristoyl Tetrapeptide-34\\n': {'startcol': 0,\n",
       "   'fulllength': 97,\n",
       "   'actuallenght': 96},\n",
       "  'has been developed to maximally and effectively inhibit       l Powder purity : 95 % up\\n': {'startcol': 0,\n",
       "   'fulllength': 88,\n",
       "   'actuallenght': 87},\n",
       "  'these matrix degrading MMPs and to restore collagen-          l Preservative : None\\n': {'startcol': 0,\n",
       "   'fulllength': 84,\n",
       "   'actuallenght': 83},\n",
       "  'levels back to normal. In vitro results show that\\n': {'startcol': 0,\n",
       "   'fulllength': 50,\n",
       "   'actuallenght': 49},\n",
       "  'DermaPepTM A440 greatly inhibited the expression and\\n': {'startcol': 0,\n",
       "   'fulllength': 53,\n",
       "   'actuallenght': 52},\n",
       "  'production of MMP-1 under both UV-stimulated and\\n': {'startcol': 0,\n",
       "   'fulllength': 49,\n",
       "   'actuallenght': 48},\n",
       "  'non-stimulated condition and restored collagen levels\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  'significantly. In addition, DermaPepTM A440\\n': {'startcol': 0,\n",
       "   'fulllength': 44,\n",
       "   'actuallenght': 43},\n",
       "  'considerably lowered the MMP levels that have been\\n': {'startcol': 0,\n",
       "   'fulllength': 51,\n",
       "   'actuallenght': 50},\n",
       "  'produced by ROS or RNS. Finally, in vivo clinical study\\n': {'startcol': 0,\n",
       "   'fulllength': 56,\n",
       "   'actuallenght': 55},\n",
       "  'results prove that DermaPepTM A440 is surely one of\\n': {'startcol': 0,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 51},\n",
       "  'the best antiaging agents in the market.\\n': {'startcol': 0,\n",
       "   'fulllength': 41,\n",
       "   'actuallenght': 40},\n",
       "  'ÿ              DermaPep\" A440\\n': {'startcol': 0,\n",
       "   'fulllength': 30,\n",
       "   'actuallenght': 29},\n",
       "  '              Safety\\n': {'startcol': 14,\n",
       "   'fulllength': 21,\n",
       "   'actuallenght': 6},\n",
       "  '              Cell Cytotoxicity Test                                             Skin Irritation Test\\n': {'startcol': 14,\n",
       "   'fulllength': 102,\n",
       "   'actuallenght': 87},\n",
       "  '              Hs68 cells were seeded into 96-well plates (2 x 103) and           Skin irritation test was performed on 31 healthy Asian\\n': {'startcol': 14,\n",
       "   'fulllength': 136,\n",
       "   'actuallenght': 121},\n",
       "  '              treated with different concentrations of Myristoyl                 volunteers (Spincontrol Asia (study report number IR-\\n': {'startcol': 14,\n",
       "   'fulllength': 135,\n",
       "   'actuallenght': 120},\n",
       "  '              Tetrapeptide-34 for 24 hours. Cell viability was                   6Q01-MW-DE08), Bangkok, Thailand).\\n': {'startcol': 14,\n",
       "   'fulllength': 116,\n",
       "   'actuallenght': 101},\n",
       "  '              assessed by MTT assay and was shown relative to\\n': {'startcol': 14,\n",
       "   'fulllength': 62,\n",
       "   'actuallenght': 47},\n",
       "  '              untreated control. Absorbance was measured by an                   Evaluation and grading of skin irritation\\n': {'startcol': 14,\n",
       "   'fulllength': 123,\n",
       "   'actuallenght': 108},\n",
       "  '                                                                                 l Erythema (no redness = 0 to very strong redness=5)\\n': {'startcol': 81,\n",
       "   'fulllength': 134,\n",
       "   'actuallenght': 52},\n",
       "  '              ELISA reader at 540 nm.\\n': {'startcol': 14,\n",
       "   'fulllength': 38,\n",
       "   'actuallenght': 23},\n",
       "  '                                                                                   After 24 hrs, mean score = 0.00 (max = 0)\\n': {'startcol': 83,\n",
       "   'fulllength': 125,\n",
       "   'actuallenght': 41},\n",
       "  '                                                                                   After 48 hrs, mean score = 0.00 (max = 0)\\n': {'startcol': 83,\n",
       "   'fulllength': 125,\n",
       "   'actuallenght': 41},\n",
       "  '                                                                                 l Oedema (no oedema = 0 to very strong oedema =5)\\n': {'startcol': 81,\n",
       "   'fulllength': 131,\n",
       "   'actuallenght': 49},\n",
       "  '                                                                                 l Scaling (no scaling = 0 to very strong scaling = 5)\\n': {'startcol': 81,\n",
       "   'fulllength': 135,\n",
       "   'actuallenght': 53},\n",
       "  '                                                                                 Mutagenicity (Ames Test)\\n': {'startcol': 81,\n",
       "   'fulllength': 106,\n",
       "   'actuallenght': 24},\n",
       "  '                                                                                 Myristoyl tetrapeptide-34 at 5 different concentrations\\n': {'startcol': 81,\n",
       "   'fulllength': 137,\n",
       "   'actuallenght': 55},\n",
       "  '                                                                                 (30,60,90,180, 360 ppm) were evaluated to predict its\\n': {'startcol': 81,\n",
       "   'fulllength': 135,\n",
       "   'actuallenght': 53},\n",
       "  '                                                                                 potential to cause mutagenicity. Five different\\n': {'startcol': 81,\n",
       "   'fulllength': 129,\n",
       "   'actuallenght': 47},\n",
       "  '                                                                                 auxotrophic mutants were used to assesse directly or in\\n': {'startcol': 81,\n",
       "   'fulllength': 137,\n",
       "   'actuallenght': 55},\n",
       "  '                                                                                 the presence of liver S9 fractions.\\n': {'startcol': 81,\n",
       "   'fulllength': 117,\n",
       "   'actuallenght': 35},\n",
       "  '              MTT Assay\\n': {'startcol': 14,\n",
       "   'fulllength': 24,\n",
       "   'actuallenght': 9},\n",
       "  '                                                                                 No mutagenicity was observed.\\n': {'startcol': 81,\n",
       "   'fulllength': 111,\n",
       "   'actuallenght': 29},\n",
       "  '                                120\\n': {'startcol': 32,\n",
       "   'fulllength': 36,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                                 In vitro Ocular Irritation Test\\n': {'startcol': 81,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 31},\n",
       "  '                                      100          97         100      98        DermaPep\" A440 at 3 different concentrations (2, 4,\\n': {'startcol': 38,\n",
       "   'fulllength': 133,\n",
       "   'actuallenght': 94},\n",
       "  '                                100         94           95                 95\\n': {'startcol': 32,\n",
       "   'fulllength': 79,\n",
       "   'actuallenght': 46},\n",
       "  'Cell viability (% of control)\\n': {'startcol': 0,\n",
       "   'fulllength': 30,\n",
       "   'actuallenght': 29},\n",
       "  '                                                                                 8 %) and butylene glycol were evaluated with the\\n': {'startcol': 81,\n",
       "   'fulllength': 130,\n",
       "   'actuallenght': 48},\n",
       "  '                                80                                               ocular irritection assay system (CA, USA).\\n': {'startcol': 32,\n",
       "   'fulllength': 124,\n",
       "   'actuallenght': 91},\n",
       "  '                                60                                               The ocular results demonstrated that the DermaPepTM\\n': {'startcol': 32,\n",
       "   'fulllength': 133,\n",
       "   'actuallenght': 100},\n",
       "  '                                                                                 A440 was classified as mild irritants.\\n': {'startcol': 81,\n",
       "   'fulllength': 120,\n",
       "   'actuallenght': 38},\n",
       "  '                                40\\n': {'startcol': 32,\n",
       "   'fulllength': 35,\n",
       "   'actuallenght': 2},\n",
       "  '                                20\\n': {'startcol': 32,\n",
       "   'fulllength': 35,\n",
       "   'actuallenght': 2},\n",
       "  '                                 0\\n': {'startcol': 33,\n",
       "   'fulllength': 35,\n",
       "   'actuallenght': 1},\n",
       "  '                                      0     2      5     10    17      25   30\\n': {'startcol': 38,\n",
       "   'fulllength': 79,\n",
       "   'actuallenght': 40},\n",
       "  '                                                 Concentration (ppm)\\n': {'startcol': 49,\n",
       "   'fulllength': 69,\n",
       "   'actuallenght': 19},\n",
       "  'ÿ DermaPep\" A440\\n': {'startcol': 0, 'fulllength': 17, 'actuallenght': 16},\n",
       "  ' In vitro efficacy\\n': {'startcol': 1,\n",
       "   'fulllength': 19,\n",
       "   'actuallenght': 17},\n",
       "  ' Inhibition of MMP-1 Production\\n': {'startcol': 1,\n",
       "   'fulllength': 32,\n",
       "   'actuallenght': 30},\n",
       "  '                                                                                       Inhibition of MMP-1 Production\\n': {'startcol': 87,\n",
       "   'fulllength': 118,\n",
       "   'actuallenght': 30},\n",
       "  ' Hs68 cells were seeded into 6-well plates and treated\\n': {'startcol': 1,\n",
       "   'fulllength': 55,\n",
       "   'actuallenght': 53},\n",
       "  ' with TGF-b, retinoic acid or Myristoyl Tetrapeptide-34\\n': {'startcol': 1,\n",
       "   'fulllength': 56,\n",
       "   'actuallenght': 54},\n",
       "  ' followed by UV radiation or not for 48 hours. Equal                                                 120\\n': {'startcol': 1,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 103},\n",
       "  '                                                                                                           100                     - 82 %\\n': {'startcol': 107,\n",
       "   'fulllength': 138,\n",
       "   'actuallenght': 30},\n",
       "  ' amounts of media were analyzed by ELISA assay for                                                   100\\n': {'startcol': 1,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 103},\n",
       "  '                                                                                   MMP1 production\\n': {'startcol': 83,\n",
       "   'fulllength': 99,\n",
       "   'actuallenght': 15},\n",
       "  ' MMP-I. Cell viability was used for sample\\n': {'startcol': 1,\n",
       "   'fulllength': 43,\n",
       "   'actuallenght': 41},\n",
       "  '                                                                                                      80                     71\\n': {'startcol': 102,\n",
       "   'fulllength': 128,\n",
       "   'actuallenght': 25},\n",
       "  ' standardization.\\n': {'startcol': 1, 'fulllength': 18, 'actuallenght': 16},\n",
       "  '                                                                                                      60\\n': {'startcol': 102,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 2},\n",
       "  '                                                                                    (% of control)\\n': {'startcol': 84,\n",
       "   'fulllength': 99,\n",
       "   'actuallenght': 14},\n",
       "  ' Myristoyl Tetrapeptide-34 significantly decreased\\n': {'startcol': 1,\n",
       "   'fulllength': 51,\n",
       "   'actuallenght': 49},\n",
       "  '                                                                                                      40\\n': {'startcol': 102,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 2},\n",
       "  ' MMP-1 production.                                                                                                      24\\n': {'startcol': 1,\n",
       "   'fulllength': 123,\n",
       "   'actuallenght': 121},\n",
       "  '                                                                                                                                    18\\n': {'startcol': 132,\n",
       "   'fulllength': 135,\n",
       "   'actuallenght': 2},\n",
       "  '                                                                                                      20          15                        12\\n': {'startcol': 102,\n",
       "   'fulllength': 143,\n",
       "   'actuallenght': 40},\n",
       "  '                                                                                           0\\n': {'startcol': 91,\n",
       "   'fulllength': 93,\n",
       "   'actuallenght': 1},\n",
       "  '                                                                                  TGF-²1         -               0.01   -     -      -       -     (ppm)\\n': {'startcol': 82,\n",
       "   'fulllength': 153,\n",
       "   'actuallenght': 70},\n",
       "  '                                                                                  Retinoic acid -                  -    1     -      -       -\\n': {'startcol': 82,\n",
       "   'fulllength': 143,\n",
       "   'actuallenght': 60},\n",
       "  '                                                                                  Myristoyl\\n': {'startcol': 82,\n",
       "   'fulllength': 92,\n",
       "   'actuallenght': 9},\n",
       "  '                                                                                                 -                -     -    5      10      20\\n': {'startcol': 97,\n",
       "   'fulllength': 143,\n",
       "   'actuallenght': 45},\n",
       "  '                                                                                  Tetrapeptide-34\\n': {'startcol': 82,\n",
       "   'fulllength': 98,\n",
       "   'actuallenght': 15},\n",
       "  'Inhibition of MMP-1 production after UVA or UVB irradiation\\n': {'startcol': 0,\n",
       "   'fulllength': 60,\n",
       "   'actuallenght': 59},\n",
       "  '                                 336                      - 128 %\\n': {'startcol': 33,\n",
       "   'fulllength': 66,\n",
       "   'actuallenght': 32},\n",
       "  '                     350                                                                             250\\n': {'startcol': 21,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 83},\n",
       "  '                                                                                                                 208                     - 137 %\\n': {'startcol': 113,\n",
       "   'fulllength': 145,\n",
       "   'actuallenght': 31},\n",
       "  '                     300\\n': {'startcol': 21,\n",
       "   'fulllength': 25,\n",
       "   'actuallenght': 3},\n",
       "  '   MMP1 production                                                                 MMP1 production\\n': {'startcol': 3,\n",
       "   'fulllength': 99,\n",
       "   'actuallenght': 95},\n",
       "  '                                                                                                     200\\n': {'startcol': 101,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 3},\n",
       "  '                     250\\n': {'startcol': 21,\n",
       "   'fulllength': 25,\n",
       "   'actuallenght': 3},\n",
       "  '                     200                    160 167                                                  150\\n': {'startcol': 21,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 83},\n",
       "  '                                                                                                                             107\\n': {'startcol': 125,\n",
       "   'fulllength': 129,\n",
       "   'actuallenght': 3},\n",
       "  '    (% of control)\\n': {'startcol': 4,\n",
       "   'fulllength': 19,\n",
       "   'actuallenght': 14},\n",
       "  '                                                                                                           100          98\\n': {'startcol': 107,\n",
       "   'fulllength': 123,\n",
       "   'actuallenght': 15},\n",
       "  '                     150                                                                                                            95\\n': {'startcol': 21,\n",
       "   'fulllength': 135,\n",
       "   'actuallenght': 113},\n",
       "  '                           100         98             92                                             100\\n': {'startcol': 27,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 77},\n",
       "  '                     100                                                                                                                    59\\n': {'startcol': 21,\n",
       "   'fulllength': 143,\n",
       "   'actuallenght': 121},\n",
       "  '                      50                                    32   21     34                            50\\n': {'startcol': 22,\n",
       "   'fulllength': 105,\n",
       "   'actuallenght': 82},\n",
       "  '                      0                                                                               0\\n': {'startcol': 22,\n",
       "   'fulllength': 104,\n",
       "   'actuallenght': 81},\n",
       "  '  UVA 30J/cm2 -                  +       + +     +    +      +      +   + (ppm)\\n': {'startcol': 2,\n",
       "   'fulllength': 80,\n",
       "   'actuallenght': 77},\n",
       "  '                                                                                  UVB 80mJ/cm2 -                  +     +     +      +      +      (ppm)\\n': {'startcol': 82,\n",
       "   'fulllength': 153,\n",
       "   'actuallenght': 70},\n",
       "  '  TGF-²1        -                      0.01      -    -      -      -   -\\n': {'startcol': 2,\n",
       "   'fulllength': 74,\n",
       "   'actuallenght': 71},\n",
       "  '                                                                                  Retinoic acid   -                     1     -      -      -\\n': {'startcol': 82,\n",
       "   'fulllength': 142,\n",
       "   'actuallenght': 59},\n",
       "  '  Retinoic acid -                           1    -    -      -      -   -\\n': {'startcol': 2,\n",
       "   'fulllength': 74,\n",
       "   'actuallenght': 71},\n",
       "  '  Myristoyl                                                                                       -                           5     10      20\\n': {'startcol': 2,\n",
       "   'fulllength': 143,\n",
       "   'actuallenght': 140},\n",
       "  '                -                                2    5     10 20 30              Tetrapeptide-34\\n': {'startcol': 16,\n",
       "   'fulllength': 98,\n",
       "   'actuallenght': 81},\n",
       "  '  Tetrapeptide-34\\n': {'startcol': 2, 'fulllength': 18, 'actuallenght': 15},\n",
       "  'In vitro efficacy\\n': {'startcol': 0, 'fulllength': 18, 'actuallenght': 17},\n",
       "  'Effect on Procollagen 1 Production                                 Changes in MMP-1 and ECM gene expression\\n': {'startcol': 0,\n",
       "   'fulllength': 108,\n",
       "   'actuallenght': 107},\n",
       "  'Hs68 cells were seeded into 6-well plates and treated              Hs68 cells were seeded into 6-well plates and treated\\n': {'startcol': 0,\n",
       "   'fulllength': 121,\n",
       "   'actuallenght': 120},\n",
       "  'with retinoic acid or Myristoyl Tetrapeptide-34                    with TGF-b, retinoic acid or Myristoyl terapeptide-34\\n': {'startcol': 0,\n",
       "   'fulllength': 121,\n",
       "   'actuallenght': 120},\n",
       "  'followed by 30J/cm2 UVA. After 48 hours equal                      followed by 30J/cm2 UVA. After 48 hours, total cellular\\n': {'startcol': 0,\n",
       "   'fulllength': 123,\n",
       "   'actuallenght': 122},\n",
       "  'amounts of cell lysates were subjected to                          RNA was extracted and reverse-transcription PCR was\\n': {'startcol': 0,\n",
       "   'fulllength': 119,\n",
       "   'actuallenght': 118},\n",
       "  'electrophoresis and analyzed by western blot for                   performed to determine MMP-1, procollagen 1,\\n': {'startcol': 0,\n",
       "   'fulllength': 112,\n",
       "   'actuallenght': 111},\n",
       "  'procollagen type I.                                                fibronectin. GAPDH mRNA level was used for sample\\n': {'startcol': 0,\n",
       "   'fulllength': 117,\n",
       "   'actuallenght': 116},\n",
       "  '                                                                   standardization.\\n': {'startcol': 67,\n",
       "   'fulllength': 84,\n",
       "   'actuallenght': 16},\n",
       "  'Myristoyl Tetrapeptide-34 significantly stimulated the\\n': {'startcol': 0,\n",
       "   'fulllength': 55,\n",
       "   'actuallenght': 54},\n",
       "  'production of type I procollagen.                                  Myristoyl Tetrapeptide-34 significantly inhibited UVA\\n': {'startcol': 0,\n",
       "   'fulllength': 121,\n",
       "   'actuallenght': 120},\n",
       "  '                                                                   stimulated MMP-1 expression and stimulated the\\n': {'startcol': 67,\n",
       "   'fulllength': 114,\n",
       "   'actuallenght': 46},\n",
       "  '                                                                   procollagen-1 and fibronectin expression.\\n': {'startcol': 67,\n",
       "   'fulllength': 109,\n",
       "   'actuallenght': 41},\n",
       "  'Stimulation of Procollagen I Production                               Changes in MMP-1 and ECM gene expression\\n': {'startcol': 0,\n",
       "   'fulllength': 111,\n",
       "   'actuallenght': 110},\n",
       "  '                               UVA irradiation\\n': {'startcol': 31,\n",
       "   'fulllength': 47,\n",
       "   'actuallenght': 15},\n",
       "  '                                                                                              UVA 30J/cm2\\n': {'startcol': 94,\n",
       "   'fulllength': 106,\n",
       "   'actuallenght': 11},\n",
       "  '                                              Myr                                                   Myr-Tetrapeptide-34\\n': {'startcol': 46,\n",
       "   'fulllength': 120,\n",
       "   'actuallenght': 73},\n",
       "  '                          NT      R.A    Tetrapeptide-34\\n': {'startcol': 26,\n",
       "   'fulllength': 57,\n",
       "   'actuallenght': 30},\n",
       "  '                                                                              NT   UVA TGF- R.A     2       5   10    20 (ppm)\\n': {'startcol': 78,\n",
       "   'fulllength': 127,\n",
       "   'actuallenght': 48},\n",
       "  '                                                                                        b1\\n': {'startcol': 88,\n",
       "   'fulllength': 91,\n",
       "   'actuallenght': 2},\n",
       "  ' Procollagen-1\\n': {'startcol': 1, 'fulllength': 15, 'actuallenght': 13},\n",
       "  '                                                              MMP-1\\n': {'startcol': 62,\n",
       "   'fulllength': 68,\n",
       "   'actuallenght': 5},\n",
       "  ' ²-actin                                                      Procollagen-1\\n': {'startcol': 1,\n",
       "   'fulllength': 76,\n",
       "   'actuallenght': 74},\n",
       "  '                  4                                           Fibronectin\\n': {'startcol': 18,\n",
       "   'fulllength': 74,\n",
       "   'actuallenght': 55},\n",
       "  ' Procollagen I\\n': {'startcol': 1, 'fulllength': 15, 'actuallenght': 13},\n",
       "  '                                                              GAPDH\\n': {'startcol': 62,\n",
       "   'fulllength': 68,\n",
       "   'actuallenght': 5},\n",
       "  '                  3                            2.43\\n': {'startcol': 18,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 33},\n",
       "  ' (% of control)\\n': {'startcol': 1, 'fulllength': 16, 'actuallenght': 14},\n",
       "  '                  2\\n': {'startcol': 18,\n",
       "   'fulllength': 20,\n",
       "   'actuallenght': 1},\n",
       "  '                      1         1.14\\n': {'startcol': 22,\n",
       "   'fulllength': 37,\n",
       "   'actuallenght': 14},\n",
       "  '                  1\\n': {'startcol': 18,\n",
       "   'fulllength': 20,\n",
       "   'actuallenght': 1},\n",
       "  '                  0\\n': {'startcol': 18,\n",
       "   'fulllength': 20,\n",
       "   'actuallenght': 1},\n",
       "  '      UVA 30J/cm2 +              +               +    (ppm)\\n': {'startcol': 6,\n",
       "   'fulllength': 60,\n",
       "   'actuallenght': 53},\n",
       "  '      Retinoic acid              1         -\\n': {'startcol': 6,\n",
       "   'fulllength': 45,\n",
       "   'actuallenght': 38},\n",
       "  '      Myristoyl\\n': {'startcol': 6, 'fulllength': 16, 'actuallenght': 9},\n",
       "  '                                                 10\\n': {'startcol': 49,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 2},\n",
       "  '      Tetrapeptide-34\\n': {'startcol': 6,\n",
       "   'fulllength': 22,\n",
       "   'actuallenght': 15},\n",
       "  'ÿ    DermaPep\" A440\\n': {'startcol': 0,\n",
       "   'fulllength': 20,\n",
       "   'actuallenght': 19},\n",
       "  '    In vitro efficacy\\n': {'startcol': 4,\n",
       "   'fulllength': 22,\n",
       "   'actuallenght': 17},\n",
       "  '    Comparison with Retinoids\\n': {'startcol': 4,\n",
       "   'fulllength': 30,\n",
       "   'actuallenght': 25},\n",
       "  '    Hs68 cells were seeded into 6-well plates and then\\n': {'startcol': 4,\n",
       "   'fulllength': 55,\n",
       "   'actuallenght': 50},\n",
       "  '    treated with retinyl palmitate, Myristoyl tetrapeptide-\\n': {'startcol': 4,\n",
       "   'fulllength': 60,\n",
       "   'actuallenght': 55},\n",
       "  '    34 or both (left figure) or retinol, Myristoyl\\n': {'startcol': 4,\n",
       "   'fulllength': 51,\n",
       "   'actuallenght': 46},\n",
       "  '    Tetrapeptide-34 or both(right figure) followed by\\n': {'startcol': 4,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 49},\n",
       "  '    30J/cm2 UVA . Equal amounts of media were analyzed\\n': {'startcol': 4,\n",
       "   'fulllength': 55,\n",
       "   'actuallenght': 50},\n",
       "  '    by ELISA assay for MMP-I. Cell viability was used for\\n': {'startcol': 4,\n",
       "   'fulllength': 58,\n",
       "   'actuallenght': 53},\n",
       "  '    sample standardization\\n': {'startcol': 4,\n",
       "   'fulllength': 27,\n",
       "   'actuallenght': 22},\n",
       "  '    Myristoyl Tetrapeptide-34 showed greater effect on\\n': {'startcol': 4,\n",
       "   'fulllength': 55,\n",
       "   'actuallenght': 50},\n",
       "  '    reducing MMP-1 than retinyl palmitate or retinol alone.\\n': {'startcol': 4,\n",
       "   'fulllength': 60,\n",
       "   'actuallenght': 55},\n",
       "  '    In addition, there was no synergy between retinyl\\n': {'startcol': 4,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 49},\n",
       "  '    palmitate and Myristoyl Tetrapeptide-34 or retinol and\\n': {'startcol': 4,\n",
       "   'fulllength': 59,\n",
       "   'actuallenght': 54},\n",
       "  '    Myristoyl Tetrapeptide-34, respectively.\\n': {'startcol': 4,\n",
       "   'fulllength': 45,\n",
       "   'actuallenght': 40},\n",
       "  '     Comparison with Retinyl Palmitate                                                     Comparison with Retinol on MMP-1 Inhibition\\n': {'startcol': 5,\n",
       "   'fulllength': 135,\n",
       "   'actuallenght': 129},\n",
       "  '     on MMP-1 Inhibition\\n': {'startcol': 5,\n",
       "   'fulllength': 25,\n",
       "   'actuallenght': 19},\n",
       "  '                                    339                                                                                  327\\n': {'startcol': 36,\n",
       "   'fulllength': 125,\n",
       "   'actuallenght': 88},\n",
       "  '                        350                                                                                  350\\n': {'startcol': 24,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 88},\n",
       "  '                                               298                                                                                   291\\n': {'startcol': 47,\n",
       "   'fulllength': 137,\n",
       "   'actuallenght': 89},\n",
       "  '                        300                                                                                  300\\n': {'startcol': 24,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 88},\n",
       "  '                                                          252\\n': {'startcol': 58,\n",
       "   'fulllength': 62,\n",
       "   'actuallenght': 3},\n",
       "  '      MMP1 production                                                                      MMP1 production\\n': {'startcol': 6,\n",
       "   'fulllength': 107,\n",
       "   'actuallenght': 100},\n",
       "  '                        250                                                                                  250\\n': {'startcol': 24,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 88},\n",
       "  '                                                                     207                                                       195\\n': {'startcol': 69,\n",
       "   'fulllength': 131,\n",
       "   'actuallenght': 61},\n",
       "  '                        200                                                                                  200\\n': {'startcol': 24,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 88},\n",
       "  '                        150                                                                                  150\\n': {'startcol': 24,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 88},\n",
       "  '       (% of control)                                                                       (% of control)\\n': {'startcol': 7,\n",
       "   'fulllength': 107,\n",
       "   'actuallenght': 99},\n",
       "  '                              100                                                                                  100                     112   101\\n': {'startcol': 30,\n",
       "   'fulllength': 149,\n",
       "   'actuallenght': 118},\n",
       "  '                                          97\\n': {'startcol': 42,\n",
       "   'fulllength': 45,\n",
       "   'actuallenght': 2},\n",
       "  '                        100                          71                                                      100\\n': {'startcol': 24,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 88},\n",
       "  '                                                                46         45     47\\n': {'startcol': 64,\n",
       "   'fulllength': 85,\n",
       "   'actuallenght': 20},\n",
       "  '                         50                                                                                   50\\n': {'startcol': 25,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 87},\n",
       "  '                         0                                                                                    0\\n': {'startcol': 25,\n",
       "   'fulllength': 112,\n",
       "   'actuallenght': 86},\n",
       "  'UVA 30J/cm2                    -    +     +     +    +     +    +     +    +      +     UVA 30J/cm2       -       +             +     +     +     +\\n': {'startcol': 0,\n",
       "   'fulllength': 148,\n",
       "   'actuallenght': 147},\n",
       "  'Retinoic acid                             1                                             Retinoic acid                           1    -     -      -\\n': {'startcol': 0,\n",
       "   'fulllength': 148,\n",
       "   'actuallenght': 147},\n",
       "  'Retinyl palmitate                              10    10   20 20      25 25        -     Retinol                                 -    5     5      -\\n': {'startcol': 0,\n",
       "   'fulllength': 148,\n",
       "   'actuallenght': 147},\n",
       "  'Myristoyl Tetrapeptide-34                 -     -    10    -    10    -    10     10    Myristoyl Tetrapeptide-34               -     -    10     10\\n': {'startcol': 0,\n",
       "   'fulllength': 149,\n",
       "   'actuallenght': 148},\n",
       "  '                                                                                (ppm)                                                            (ppm)\\n': {'startcol': 80,\n",
       "   'fulllength': 151,\n",
       "   'actuallenght': 70},\n",
       "  'Signaling of MMP-1 expression\\n': {'startcol': 0,\n",
       "   'fulllength': 30,\n",
       "   'actuallenght': 29},\n",
       "  '                                                             AP-1 component gene expression(PCR)\\n': {'startcol': 61,\n",
       "   'fulllength': 97,\n",
       "   'actuallenght': 35},\n",
       "  'Hs68 cells were seeded into 6-well plates and\\n': {'startcol': 0,\n",
       "   'fulllength': 46,\n",
       "   'actuallenght': 45},\n",
       "  'pretreated with the retinoic acid or Myristoyl\\n': {'startcol': 0,\n",
       "   'fulllength': 47,\n",
       "   'actuallenght': 46},\n",
       "  'Tetrapeptide-34 for 24 and then stimulated by UV                           c-fos\\n': {'startcol': 0,\n",
       "   'fulllength': 81,\n",
       "   'actuallenght': 80},\n",
       "  'irradiation. After 30 minutes, total cellular RNA was\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  '                                                                           c-jun\\n': {'startcol': 75,\n",
       "   'fulllength': 81,\n",
       "   'actuallenght': 5},\n",
       "  'extracted and reverse-transcription PCR was performed\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  'to determine c-jun and c-fos mRNA level. b-actin was                       GAPDH\\n': {'startcol': 0,\n",
       "   'fulllength': 81,\n",
       "   'actuallenght': 80},\n",
       "  'used for sample standardization.\\n': {'startcol': 0,\n",
       "   'fulllength': 33,\n",
       "   'actuallenght': 32},\n",
       "  '                                                                 UV                         -         +            +        +     +\\n': {'startcol': 65,\n",
       "   'fulllength': 132,\n",
       "   'actuallenght': 66},\n",
       "  'Myristoyl Tetrapeptide-34 significantly decreased UVB            Myristoyl Tetrapeptide-34                         5        10   20 (ppm)\\n': {'startcol': 0,\n",
       "   'fulllength': 138,\n",
       "   'actuallenght': 137},\n",
       "  'induced c-fos mRNA expression\\n': {'startcol': 0,\n",
       "   'fulllength': 30,\n",
       "   'actuallenght': 29},\n",
       "  ' Mechanism of MMP-1 expression                               c-fos/c-Jun gene expression\\n': {'startcol': 1,\n",
       "   'fulllength': 89,\n",
       "   'actuallenght': 87},\n",
       "  '                                                                                            125\\n': {'startcol': 92,\n",
       "   'fulllength': 96,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                           120                  110        108                    108\\n': {'startcol': 75,\n",
       "   'fulllength': 134,\n",
       "   'actuallenght': 58},\n",
       "  '                                                                                                                        107\\n': {'startcol': 120,\n",
       "   'fulllength': 124,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                                      100\\n': {'startcol': 86,\n",
       "   'fulllength': 90,\n",
       "   'actuallenght': 3},\n",
       "  '                                                             mRNA expression\\n': {'startcol': 61,\n",
       "   'fulllength': 77,\n",
       "   'actuallenght': 15},\n",
       "  '                                                                                    100\\n': {'startcol': 84,\n",
       "   'fulllength': 88,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                           100                                                            c-fos\\n': {'startcol': 75,\n",
       "   'fulllength': 144,\n",
       "   'actuallenght': 68},\n",
       "  '                                                                                                                                          c-jun\\n': {'startcol': 138,\n",
       "   'fulllength': 144,\n",
       "   'actuallenght': 5},\n",
       "  '                                                                               80\\n': {'startcol': 79,\n",
       "   'fulllength': 82,\n",
       "   'actuallenght': 2},\n",
       "  '                                                              (% of control)\\n': {'startcol': 62,\n",
       "   'fulllength': 77,\n",
       "   'actuallenght': 14},\n",
       "  '                                                                                                          61\\n': {'startcol': 106,\n",
       "   'fulllength': 109,\n",
       "   'actuallenght': 2},\n",
       "  '                                                                               60                                      55\\n': {'startcol': 79,\n",
       "   'fulllength': 122,\n",
       "   'actuallenght': 42},\n",
       "  '                                                                                                                                 41\\n': {'startcol': 129,\n",
       "   'fulllength': 132,\n",
       "   'actuallenght': 2},\n",
       "  '                                                                               40\\n': {'startcol': 79,\n",
       "   'fulllength': 82,\n",
       "   'actuallenght': 2},\n",
       "  '                                                                               20\\n': {'startcol': 79,\n",
       "   'fulllength': 82,\n",
       "   'actuallenght': 2},\n",
       "  '                                                        UV                            -         +          +                +         +\\n': {'startcol': 56,\n",
       "   'fulllength': 136,\n",
       "   'actuallenght': 79},\n",
       "  '                                                        Myristoyl Tetrapeptide-34                              5        10        20 (ppm)\\n': {'startcol': 56,\n",
       "   'fulllength': 139,\n",
       "   'actuallenght': 82},\n",
       "  'Inhibition of ROS Induced MMP-1\\n': {'startcol': 0,\n",
       "   'fulllength': 32,\n",
       "   'actuallenght': 31},\n",
       "  'Production and AP-1 Signaling\\n': {'startcol': 0,\n",
       "   'fulllength': 30,\n",
       "   'actuallenght': 29},\n",
       "  'Hs68 cells were seeded into 6-well plates and treated\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  'with Myristoyl Tetrapeptide-34 followed by or H2O2.\\n': {'startcol': 0,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 51},\n",
       "  'Equal amounts of media were analyzed by ELISA assay\\n': {'startcol': 0,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 51},\n",
       "  'for MMP-I. Cell viability was used for sample\\n': {'startcol': 0,\n",
       "   'fulllength': 46,\n",
       "   'actuallenght': 45},\n",
       "  'standardization. For AP-1 signaling, total cellular RNA\\n': {'startcol': 0,\n",
       "   'fulllength': 56,\n",
       "   'actuallenght': 55},\n",
       "  'was extracted and reverse-transcription PCR was\\n': {'startcol': 0,\n",
       "   'fulllength': 48,\n",
       "   'actuallenght': 47},\n",
       "  'performed to determine c-jun and c-fos mRNA level.\\n': {'startcol': 0,\n",
       "   'fulllength': 51,\n",
       "   'actuallenght': 50},\n",
       "  'GAPDH was used for sample standardization.\\n': {'startcol': 0,\n",
       "   'fulllength': 43,\n",
       "   'actuallenght': 42},\n",
       "  'Myristoyl Tetrapeptide-34 significantly decreased ROS\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  'radical stimulated MMP-1 production and c-fos mRNA\\n': {'startcol': 0,\n",
       "   'fulllength': 51,\n",
       "   'actuallenght': 50},\n",
       "  'expression.\\n': {'startcol': 0, 'fulllength': 12, 'actuallenght': 11},\n",
       "  '   Inhibition of MMP-1 production against                        AP-1 component gene expression(PCR)\\n': {'startcol': 3,\n",
       "   'fulllength': 101,\n",
       "   'actuallenght': 97},\n",
       "  '   H2O2\\n': {'startcol': 3, 'fulllength': 8, 'actuallenght': 4},\n",
       "  '                                                                              c-fos\\n': {'startcol': 78,\n",
       "   'fulllength': 84,\n",
       "   'actuallenght': 5},\n",
       "  '                                                                              c-jun\\n': {'startcol': 78,\n",
       "   'fulllength': 84,\n",
       "   'actuallenght': 5},\n",
       "  '                                 153        - 149 %\\n': {'startcol': 33,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 18},\n",
       "  '                     150                                                      GAPDH\\n': {'startcol': 21,\n",
       "   'fulllength': 84,\n",
       "   'actuallenght': 62},\n",
       "  '   MMP1 production\\n': {'startcol': 3,\n",
       "   'fulllength': 19,\n",
       "   'actuallenght': 15},\n",
       "  '                                                                                                 208\\n': {'startcol': 97,\n",
       "   'fulllength': 101,\n",
       "   'actuallenght': 3},\n",
       "  '                           100                                                 200\\n': {'startcol': 27,\n",
       "   'fulllength': 83,\n",
       "   'actuallenght': 55},\n",
       "  '                     100               88\\n': {'startcol': 21,\n",
       "   'fulllength': 42,\n",
       "   'actuallenght': 20},\n",
       "  '                                                                 mRNA expression\\n': {'startcol': 65,\n",
       "   'fulllength': 81,\n",
       "   'actuallenght': 15},\n",
       "  '                                              74\\n': {'startcol': 46,\n",
       "   'fulllength': 49,\n",
       "   'actuallenght': 2},\n",
       "  '                                                                                   150\\n': {'startcol': 83,\n",
       "   'fulllength': 87,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                                                  119    118    115    120\\n': {'startcol': 98,\n",
       "   'fulllength': 123,\n",
       "   'actuallenght': 24},\n",
       "  '                     50                                                                    100\\n': {'startcol': 21,\n",
       "   'fulllength': 95,\n",
       "   'actuallenght': 73},\n",
       "  '                                                                                         100                                 c-fos\\n': {'startcol': 89,\n",
       "   'fulllength': 131,\n",
       "   'actuallenght': 41},\n",
       "  '                                                                  (% of control)\\n': {'startcol': 66,\n",
       "   'fulllength': 81,\n",
       "   'actuallenght': 14},\n",
       "  '                                                                               100                      77            84     c-jun\\n': {'startcol': 79,\n",
       "   'fulllength': 131,\n",
       "   'actuallenght': 51},\n",
       "  '                                                                                                               75\\n': {'startcol': 111,\n",
       "   'fulllength': 114,\n",
       "   'actuallenght': 2},\n",
       "  '                      0\\n': {'startcol': 22,\n",
       "   'fulllength': 24,\n",
       "   'actuallenght': 1},\n",
       "  '                                                                                   50\\n': {'startcol': 83,\n",
       "   'fulllength': 86,\n",
       "   'actuallenght': 2},\n",
       "  '  H2O2 (500uM) -                 +     +       +      (ppm)\\n': {'startcol': 2,\n",
       "   'fulllength': 60,\n",
       "   'actuallenght': 57},\n",
       "  '  Myristoyl\\n': {'startcol': 2, 'fulllength': 12, 'actuallenght': 9},\n",
       "  '                  -                    5      10                        0\\n': {'startcol': 18,\n",
       "   'fulllength': 74,\n",
       "   'actuallenght': 55},\n",
       "  '  Tetrapeptide-34                                             H2O2 (500uM)                 -       +     +      +     +\\n': {'startcol': 2,\n",
       "   'fulllength': 120,\n",
       "   'actuallenght': 117},\n",
       "  '                                                              Myristoyl Tetrapeptide-34                  5     10     20 (ppm)\\n': {'startcol': 62,\n",
       "   'fulllength': 127,\n",
       "   'actuallenght': 64},\n",
       "  'Inhibition of RNS Induced MMP-1\\n': {'startcol': 0,\n",
       "   'fulllength': 32,\n",
       "   'actuallenght': 31},\n",
       "  'with the Myristoyl Tetrapeptide-34 followed by\\n': {'startcol': 0,\n",
       "   'fulllength': 47,\n",
       "   'actuallenght': 46},\n",
       "  'SNAP(S-nitroso-N-acetylpenicillamine. Equal amounts\\n': {'startcol': 0,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 51},\n",
       "  'of media were analyzed by ELISA assay for MMP-I. Cell\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  'viability was used for sample standardization. For AP-1\\n': {'startcol': 0,\n",
       "   'fulllength': 56,\n",
       "   'actuallenght': 55},\n",
       "  'signaling, total cellular RNA was extracted and reverse-\\n': {'startcol': 0,\n",
       "   'fulllength': 57,\n",
       "   'actuallenght': 56},\n",
       "  'transcription PCR was performed to determine c-jun\\n': {'startcol': 0,\n",
       "   'fulllength': 51,\n",
       "   'actuallenght': 50},\n",
       "  'and c-fos mRNA level. GAPDH was used for sample\\n': {'startcol': 0,\n",
       "   'fulllength': 48,\n",
       "   'actuallenght': 47},\n",
       "  'standardization.\\n': {'startcol': 0, 'fulllength': 17, 'actuallenght': 16},\n",
       "  'Myristoyl Tetrapeptide-34 significantly decreased RNS\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  ' Inhibition of MMP-1 production against                          AP-1 component gene expression(PCR)\\n': {'startcol': 1,\n",
       "   'fulllength': 101,\n",
       "   'actuallenght': 99},\n",
       "  ' SNAP\\n': {'startcol': 1, 'fulllength': 6, 'actuallenght': 4},\n",
       "  '                                                                          c-fos\\n': {'startcol': 74,\n",
       "   'fulllength': 80,\n",
       "   'actuallenght': 5},\n",
       "  '                                                                          c-jun\\n': {'startcol': 74,\n",
       "   'fulllength': 80,\n",
       "   'actuallenght': 5},\n",
       "  '                                185         - 115 %\\n': {'startcol': 32,\n",
       "   'fulllength': 52,\n",
       "   'actuallenght': 19},\n",
       "  '                                                                          GAPDH\\n': {'startcol': 74,\n",
       "   'fulllength': 80,\n",
       "   'actuallenght': 5},\n",
       "  '  MMP1 production\\n': {'startcol': 2, 'fulllength': 18, 'actuallenght': 15},\n",
       "  '                                                                           140\\n': {'startcol': 75,\n",
       "   'fulllength': 79,\n",
       "   'actuallenght': 3},\n",
       "  '                    150\\n': {'startcol': 20,\n",
       "   'fulllength': 24,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                                                127\\n': {'startcol': 96,\n",
       "   'fulllength': 100,\n",
       "   'actuallenght': 3},\n",
       "  '                                      111                                                                             120\\n': {'startcol': 38,\n",
       "   'fulllength': 122,\n",
       "   'actuallenght': 83},\n",
       "  '                                                                                                 119\\n': {'startcol': 97,\n",
       "   'fulllength': 101,\n",
       "   'actuallenght': 3},\n",
       "  '                          100                                                                           118    115\\n': {'startcol': 26,\n",
       "   'fulllength': 115,\n",
       "   'actuallenght': 88},\n",
       "  '                    100                       87                               120\\n': {'startcol': 20,\n",
       "   'fulllength': 83,\n",
       "   'actuallenght': 62},\n",
       "  '   (% of control)                                                                         100\\n': {'startcol': 3,\n",
       "   'fulllength': 94,\n",
       "   'actuallenght': 90},\n",
       "  '                                                                                        100\\n': {'startcol': 88,\n",
       "   'fulllength': 92,\n",
       "   'actuallenght': 3},\n",
       "  '                    50                                                         100                                           c-fos\\n': {'startcol': 20,\n",
       "   'fulllength': 131,\n",
       "   'actuallenght': 110},\n",
       "  '                                                                                                                     84      c-jun\\n': {'startcol': 117,\n",
       "   'fulllength': 131,\n",
       "   'actuallenght': 13},\n",
       "  '                     0                                                                                 77     75\\n': {'startcol': 21,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 91},\n",
       "  '                                                                                   80\\n': {'startcol': 83,\n",
       "   'fulllength': 86,\n",
       "   'actuallenght': 2},\n",
       "  ' SNAP(500uM) -                  +     +        +      (ppm)\\n': {'startcol': 1,\n",
       "   'fulllength': 60,\n",
       "   'actuallenght': 58},\n",
       "  ' Myristoyl                                                            60\\n': {'startcol': 1,\n",
       "   'fulllength': 73,\n",
       "   'actuallenght': 71},\n",
       "  '                 -                     5      10\\n': {'startcol': 17,\n",
       "   'fulllength': 49,\n",
       "   'actuallenght': 31},\n",
       "  ' Tetrapeptide-34\\n': {'startcol': 1, 'fulllength': 17, 'actuallenght': 15},\n",
       "  '                                                              SNAP(100uM)                 -       +     +      +      +\\n': {'startcol': 62,\n",
       "   'fulllength': 120,\n",
       "   'actuallenght': 57},\n",
       "  '                                                              Myristoyl Tetrapeptide-34                 5      10     20 (ppm)\\n': {'startcol': 62,\n",
       "   'fulllength': 127,\n",
       "   'actuallenght': 64},\n",
       "  ' Anti-inflammatory Effects of Myristoyl                      Anti-inflammatory Effects of Myristoyl\\n': {'startcol': 1,\n",
       "   'fulllength': 100,\n",
       "   'actuallenght': 98},\n",
       "  ' Tetrapeptide-34 on Human Fibroblasts                        Tetrapeptide-34 on Keratinocytes\\n': {'startcol': 1,\n",
       "   'fulllength': 94,\n",
       "   'actuallenght': 92},\n",
       "  ' Hs68 cells were seeded into 6-well plates and               Human keratinocyte HaCaT cells were treated with\\n': {'startcol': 1,\n",
       "   'fulllength': 110,\n",
       "   'actuallenght': 108},\n",
       "  ' pretreated with TGF-b, retinoic acid or Myristoyl           Myristoyl Tetrapeptide-34 and then stimulated with\\n': {'startcol': 1,\n",
       "   'fulllength': 112,\n",
       "   'actuallenght': 110},\n",
       "  ' Tetrapeptide-34 followed by 30J/cm2 UVA . After 24          UVB (100 mJ/cm2). After 24 hours, total cellular RNA\\n': {'startcol': 1,\n",
       "   'fulllength': 114,\n",
       "   'actuallenght': 112},\n",
       "  ' hours, total cellular RNA was extracted and reverse-        was extracted and reverse-transcription PCR was\\n': {'startcol': 1,\n",
       "   'fulllength': 109,\n",
       "   'actuallenght': 107},\n",
       "  ' transcription PCR was performed to determine IL-1²,         performed to determine IL-1a, IL-1², IL-6. GAPDH\\n': {'startcol': 1,\n",
       "   'fulllength': 110,\n",
       "   'actuallenght': 108},\n",
       "  ' IL-6, IL-8 . GAPDH mRNA level was used for sample           mRNA level was used for sample standardization.\\n': {'startcol': 1,\n",
       "   'fulllength': 109,\n",
       "   'actuallenght': 107},\n",
       "  ' standardization.                                            Myristoyl Tetrapeptide-34 significantly inhibited UVB-\\n': {'startcol': 1,\n",
       "   'fulllength': 116,\n",
       "   'actuallenght': 114},\n",
       "  ' Myristoyl Tetrapeptide-34 greatly inhibited UVA-            induced expression of pro-inflammatory cytokines in\\n': {'startcol': 1,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 111},\n",
       "  ' induced expression of pro-inflammatory cytokines in         human keratinocytes.\\n': {'startcol': 1,\n",
       "   'fulllength': 82,\n",
       "   'actuallenght': 80},\n",
       "  ' human skin fibroblasts.\\n': {'startcol': 1,\n",
       "   'fulllength': 25,\n",
       "   'actuallenght': 23},\n",
       "  '  Pro-inflammatory cytokines Level (Hs68)                    Pro-inflammatory cytokines Level (HaCaT)\\n': {'startcol': 2,\n",
       "   'fulllength': 102,\n",
       "   'actuallenght': 99},\n",
       "  '                                                                                              UVB\\n': {'startcol': 94,\n",
       "   'fulllength': 98,\n",
       "   'actuallenght': 3},\n",
       "  '                            UVA 30J/cm2                                                    Myr-Tetrapeptide-34\\n': {'startcol': 28,\n",
       "   'fulllength': 111,\n",
       "   'actuallenght': 82},\n",
       "  '                                                                                 NT              1    5     (ppm)\\n': {'startcol': 81,\n",
       "   'fulllength': 114,\n",
       "   'actuallenght': 32},\n",
       "  '                                  Myr-Tetrapeptide-34\\n': {'startcol': 34,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 19},\n",
       "  '          NT    UVA TGF- R.A       2     5    10    20 (ppm)           IL-1±\\n': {'startcol': 10,\n",
       "   'fulllength': 77,\n",
       "   'actuallenght': 66},\n",
       "  '                        b1\\n': {'startcol': 24,\n",
       "   'fulllength': 27,\n",
       "   'actuallenght': 2},\n",
       "  'IL-1b                                                                  IL-1²\\n': {'startcol': 0,\n",
       "   'fulllength': 77,\n",
       "   'actuallenght': 76},\n",
       "  'IL-6\\n': {'startcol': 0, 'fulllength': 5, 'actuallenght': 4},\n",
       "  '                                                                       IL-6\\n': {'startcol': 71,\n",
       "   'fulllength': 76,\n",
       "   'actuallenght': 4},\n",
       "  'IL-8\\n': {'startcol': 0, 'fulllength': 5, 'actuallenght': 4},\n",
       "  '                                                                       IL-8\\n': {'startcol': 71,\n",
       "   'fulllength': 76,\n",
       "   'actuallenght': 4},\n",
       "  'GAPDH\\n': {'startcol': 0, 'fulllength': 6, 'actuallenght': 5},\n",
       "  '                                                                       GAPDH\\n': {'startcol': 71,\n",
       "   'fulllength': 77,\n",
       "   'actuallenght': 5},\n",
       "  'DNA Chip Assay\\n': {'startcol': 0, 'fulllength': 15, 'actuallenght': 14},\n",
       "  'CHIP data of pro-inflammatory related gene\\n': {'startcol': 0,\n",
       "   'fulllength': 43,\n",
       "   'actuallenght': 42},\n",
       "  '                                                                                                        Gene       Genbank                   A440/UV\\n': {'startcol': 104,\n",
       "   'fulllength': 149,\n",
       "   'actuallenght': 44},\n",
       "  '  Index      ProbeName                                     Description                                                        UniGeneID\\n': {'startcol': 2,\n",
       "   'fulllength': 136,\n",
       "   'actuallenght': 133},\n",
       "  '                                                                                                       Symbol      Accession                 intensity\\n': {'startcol': 103,\n",
       "   'fulllength': 151,\n",
       "   'actuallenght': 47},\n",
       "  '                          tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), trans\\n': {'startcol': 26,\n",
       "   'fulllength': 97,\n",
       "   'actuallenght': 70},\n",
       "  '     1078 A_23_P121253                                                                              TNFSF10      NM_003810    Hs.478275     0.712051591\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '                          cript variant 1, mRNA\\n': {'startcol': 26,\n",
       "   'fulllength': 48,\n",
       "   'actuallenght': 21},\n",
       "  '                          tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B), tra\\n': {'startcol': 26,\n",
       "   'fulllength': 97,\n",
       "   'actuallenght': 70},\n",
       "  '     2139 A_23_P14174                                                                               TNFSF13B     NM_006573    Hs.525157     0.444733865\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '                          nscript variant 1, mRNA\\n': {'startcol': 26,\n",
       "   'fulllength': 50,\n",
       "   'actuallenght': 23},\n",
       "  '     7521 A_23_P376488    tumor necrosis factor (TNF), mRNA                                         TNF          NM_000594    Hs.241570     0.679159864\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '     3365 A_23_P165624    tumor necrosis   factor, alpha-induced protein 6 (TNFAIP6), mRNA          TNFAIP6      NM_007115    Hs.437322     0.542426693\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '                          tumor necrosis   factor receptor superfamily, member 11b (TNFRSF11B),\\n': {'startcol': 26,\n",
       "   'fulllength': 96,\n",
       "   'actuallenght': 69},\n",
       "  '    10479 A_23_P71530                                                                               TNFRSF11B NM_002546       Hs.81791       0.50666134\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '                          mRNA\\n': {'startcol': 26,\n",
       "   'fulllength': 31,\n",
       "   'actuallenght': 4},\n",
       "  '                          tumor necrosis   factor receptor superfamily, member 6b, decoy (TNFRSF\\n': {'startcol': 26,\n",
       "   'fulllength': 97,\n",
       "   'actuallenght': 70},\n",
       "  '     4776 A_23_P218646                                                                              TNFRSF6B     NM_003823    Hs.434878     0.587013243\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '                          6B), mRNA\\n': {'startcol': 26,\n",
       "   'fulllength': 36,\n",
       "   'actuallenght': 9},\n",
       "  '    25168 A_33_P3305571                                                                             TNFRSF6B     NM_003823    Hs.434878     0.589897775\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '     1337 A_23_P126836    tumor necrosis   factor (ligand) superfamily, member 4 (TNFSF4), mRNA     TNFSF4       NM_003326    Hs.181097     0.858187786\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '    21238 A_33_P3246833   interleukin 1 receptor antagonist (IL1RN), transcript variant 4, mRNA     IL1RN        NM_173843    Hs.81134      0.398674612\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '    12985 A_24_P200023    interleukin 1 receptor, type I (IL1R1), mRNA                              IL1R1        NM_000877    Hs.701982     0.547208757\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '    31154 A_33_P3396389   interleukin 1 receptor, type I (IL1R1), mRNA                              IL1R1        NM_000877    Hs.701982     0.654729398\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '                          interleukin 1 receptor-associated kinase 1 (IRAK1), transcript variant 1,\\n': {'startcol': 26,\n",
       "   'fulllength': 100,\n",
       "   'actuallenght': 73},\n",
       "  '    10576 A_23_P73780                                                                               IRAK1        NM_001569    Hs.522819     0.826588326\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '    11156 A_23_P85209     interleukin 13 receptor, alpha 2 (IL13RA2), mRNA                          IL13RA2      NM_000640    Hs.336046     0.454015552\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '     1964 A_23_P138680    interleukin 15 receptor, alpha (IL15RA), transcript variant 2, mRNA       IL15RA       NM_172200    Hs.524117     0.696403722\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '                          peroxisome proliferator-activated receptor gamma (PPARG), transcript v\\n': {'startcol': 26,\n",
       "   'fulllength': 97,\n",
       "   'actuallenght': 70},\n",
       "  '     5072 A_23_P252062                                                                              PPARG        NM_138711    Hs.162646     0.620602594\\n': {'startcol': 5,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 146},\n",
       "  '                          ariant 3, mRNA\\n': {'startcol': 26,\n",
       "   'fulllength': 41,\n",
       "   'actuallenght': 14},\n",
       "  '    28110 A_33_P3350726                                                                             PPARG        NM_138711    Hs.162646     0.587618207\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  'CHIP data of ECM protein related gene\\n': {'startcol': 0,\n",
       "   'fulllength': 38,\n",
       "   'actuallenght': 37},\n",
       "  '                                                                                                Gene     Genbank                   UV/NT        A440/UV\\n': {'startcol': 96,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 55},\n",
       "  ' Index      ProbeName                                  Description                                                  UniGeneID\\n': {'startcol': 1,\n",
       "   'fulllength': 126,\n",
       "   'actuallenght': 124},\n",
       "  '                                                                                               Symbol    Accession                intensity     intensity\\n': {'startcol': 95,\n",
       "   'fulllength': 154,\n",
       "   'actuallenght': 58},\n",
       "  '   25105 A_33_P3304668  collagen, type I, alpha 1 (COL1A1), mRNA                             COL1A1     NM_000088 Hs.172928     0.445770446 1.932809889\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '   11097 A_23_P83818    collagen, type V, alpha 1 (COL5A1), mRNA                             COL5A1     NM_000093 Hs.210283     0.749845964 1.621188441\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '   33475 A_33_P3629678  collagen, type V, alpha 1 (COL5A1), mRNA                             COL5A1     NM_000093 Hs.210283     0.559161349 1.618872875\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '   31278 A_33_P3398236  collagen, type XXVIII, alpha 1                                       COL28A1    AJ890452    Hs.491104   0.934087883 3.457301057\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '   14419 A_24_P334130   fibronectin 1 (FN1), transcript variant 7, mRNA                      FN1        NM_054034 Hs.203717     0.850157729 2.353647741\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '    2910 A_23_P156327   transforming growth factor, beta-induced, 68kDa (TGFBI), mRNA TGFBI             NM_000358 Hs.369397     0.682829566 2.148446928\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '   25707 A_33_P3313825  transforming growth factor, beta receptor II (70/80kDa)              TGFBR2     AJ786388    Hs.82028                    1.62420191\\n': {'startcol': 3,\n",
       "   'fulllength': 155,\n",
       "   'actuallenght': 151},\n",
       "  '                        transforming growth factor, beta 2 (TGFB2), transcript variant 2,\\n': {'startcol': 24,\n",
       "   'fulllength': 90,\n",
       "   'actuallenght': 65},\n",
       "  '   15179 A_24_P402438                                                                        TGFB2      NM_003238 Hs.133379     0.971181556     1.69905287\\n': {'startcol': 3,\n",
       "   'fulllength': 155,\n",
       "   'actuallenght': 151},\n",
       "  '                        mRNA\\n': {'startcol': 24,\n",
       "   'fulllength': 29,\n",
       "   'actuallenght': 4},\n",
       "  '                        latent transforming growth factor beta binding protein 2 (LTBP2)\\n': {'startcol': 24,\n",
       "   'fulllength': 89,\n",
       "   'actuallenght': 64},\n",
       "  '    8176 A_23_P405129                                                                        LTBP2      NM_000428 Hs.512776     1.024822695     2.42692819\\n': {'startcol': 4,\n",
       "   'fulllength': 155,\n",
       "   'actuallenght': 150},\n",
       "  '                        , mRNA\\n': {'startcol': 24,\n",
       "   'fulllength': 31,\n",
       "   'actuallenght': 6},\n",
       "  '    3781 A_23_P19663    connective tissue growth factor (CTGF), mRNA                         CTGF       NM_001901 Hs.410037     0.332717584 3.151554741\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '   30141 A_33_P3380797  fibroblast growth factor 3 (FGF3), mRNA                              FGF3       NM_005247 Hs.37092      0.965838192 2.016988657\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '    3838 A_23_P200741   dermatopontin (DPT), mRNA [NM_001937]                                DPT        NM_001937 Hs.80552      0.762254902 1.327178047\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '                        signal transducer and activator of transcription 1, 91kDa (STAT1),\\n': {'startcol': 24,\n",
       "   'fulllength': 91,\n",
       "   'actuallenght': 66},\n",
       "  '   13766 A_24_P274270                                                                        STAT1      NM_139266 Hs.642990     2.028586279 0.346110016\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '                        transcript variant beta, mRNA\\n': {'startcol': 24,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 29},\n",
       "  '    9975 A_23_P62115    TIMP metallopeptidase inhibitor 1 (TIMP1), mRNA                      TIMP1      NM_003254 Hs.522632     0.850732951 1.517430948\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '                        matrix metallopeptidase 1 (interstitial collagenase) (MMP1), trans\\n': {'startcol': 24,\n",
       "   'fulllength': 91,\n",
       "   'actuallenght': 66},\n",
       "  '    3547 A_23_P1691                                                                          MMP1       NM_002421 Hs.83169      1.564405238 0.568818868\\n': {'startcol': 4,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 147},\n",
       "  '                        cript variant 1, mRNA\\n': {'startcol': 24,\n",
       "   'fulllength': 46,\n",
       "   'actuallenght': 21},\n",
       "  '                        matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3),\\n': {'startcol': 24,\n",
       "   'fulllength': 89,\n",
       "   'actuallenght': 64},\n",
       "  '    3181 A_23_P161698                                                                        MMP3       NM_002422 Hs.375129     2.803817166     0.82164818\\n': {'startcol': 4,\n",
       "   'fulllength': 155,\n",
       "   'actuallenght': 150},\n",
       "  '                        matrix metallopeptidase 14 (membrane-inserted) (MMP14), mRN\\n': {'startcol': 24,\n",
       "   'fulllength': 84,\n",
       "   'actuallenght': 59},\n",
       "  '   16187 A_24_P82106                                                                         MMP14      NM_004995 Hs.2399       1.135234216 0.695241922\\n': {'startcol': 3,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 148},\n",
       "  '                        A\\n': {'startcol': 24,\n",
       "   'fulllength': 26,\n",
       "   'actuallenght': 1},\n",
       "  'In vivo efficacy\\n': {'startcol': 0, 'fulllength': 17, 'actuallenght': 16},\n",
       "  'Anti-Aging Efficacy on Asian Skin Type\\n': {'startcol': 0,\n",
       "   'fulllength': 39,\n",
       "   'actuallenght': 38},\n",
       "  '                                                         Anti aging effect\\n': {'startcol': 57,\n",
       "   'fulllength': 75,\n",
       "   'actuallenght': 17},\n",
       "  'In a clinical study with 21 Asian healthy female\\n': {'startcol': 0,\n",
       "   'fulllength': 49,\n",
       "   'actuallenght': 48},\n",
       "  '                                                                                                                                     Control\\n': {'startcol': 133,\n",
       "   'fulllength': 141,\n",
       "   'actuallenght': 7},\n",
       "  'volunteers (Korea), aged 30 to 65, 2 % formula                                                                                       DermaPepTM A440\\n': {'startcol': 0,\n",
       "   'fulllength': 149,\n",
       "   'actuallenght': 148},\n",
       "  'containing DermaPep\"A440 had been applied twice                                                        R1      R2      R3     R4        R5       R6\\n': {'startcol': 0,\n",
       "   'fulllength': 148,\n",
       "   'actuallenght': 147},\n",
       "  '                                                         Variation of the reduction rate(%)\\n': {'startcol': 57,\n",
       "   'fulllength': 92,\n",
       "   'actuallenght': 34},\n",
       "  '                                                                                                 0\\n': {'startcol': 97,\n",
       "   'fulllength': 99,\n",
       "   'actuallenght': 1},\n",
       "  'daily during 12 weeks on the face area. Evaluation was\\n': {'startcol': 0,\n",
       "   'fulllength': 55,\n",
       "   'actuallenght': 54},\n",
       "  '                                                                                                 -5\\n': {'startcol': 97,\n",
       "   'fulllength': 100,\n",
       "   'actuallenght': 2},\n",
       "  'performed by Transparancy profilometry analysis using\\n': {'startcol': 0,\n",
       "   'fulllength': 54,\n",
       "   'actuallenght': 53},\n",
       "  '                                                                                                -10\\n': {'startcol': 96,\n",
       "   'fulllength': 100,\n",
       "   'actuallenght': 3},\n",
       "  'visiometer SV600(Courage-Khazaka electronic GmbH,                                                                             -8                 -8\\n': {'startcol': 0,\n",
       "   'fulllength': 148,\n",
       "   'actuallenght': 147},\n",
       "  '                                                                                                -15                   -11\\n': {'startcol': 96,\n",
       "   'fulllength': 122,\n",
       "   'actuallenght': 25},\n",
       "  'Germany) and digital photography.                                                                     -14                              -15\\n': {'startcol': 0,\n",
       "   'fulllength': 139,\n",
       "   'actuallenght': 138},\n",
       "  '                                                                                                -20\\n': {'startcol': 96,\n",
       "   'fulllength': 100,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                                                              -19\\n': {'startcol': 110,\n",
       "   'fulllength': 114,\n",
       "   'actuallenght': 3},\n",
       "  'DermaPep\"A440 showed significant improvement in                                                 -25                            -22\\n': {'startcol': 0,\n",
       "   'fulllength': 131,\n",
       "   'actuallenght': 130},\n",
       "  'all the parameters measured and proved to be the                                                -30                     -25\\n': {'startcol': 0,\n",
       "   'fulllength': 124,\n",
       "   'actuallenght': 123},\n",
       "  '                                                                                                        -27\\n': {'startcol': 104,\n",
       "   'fulllength': 108,\n",
       "   'actuallenght': 3},\n",
       "  '                                                                                                                -29                      -28\\n': {'startcol': 112,\n",
       "   'fulllength': 141,\n",
       "   'actuallenght': 28},\n",
       "  'powerful anti-wrinkle agent.                                                                    -35\\n': {'startcol': 0,\n",
       "   'fulllength': 100,\n",
       "   'actuallenght': 99},\n",
       "  '                                                                                                -40                                                   -37\\n': {'startcol': 96,\n",
       "   'fulllength': 154,\n",
       "   'actuallenght': 57},\n",
       "  '                                                         R1: Skin roughness\\n': {'startcol': 57,\n",
       "   'fulllength': 76,\n",
       "   'actuallenght': 18},\n",
       "  '                                                         R2: Maximum roughness\\n': {'startcol': 57,\n",
       "   'fulllength': 79,\n",
       "   'actuallenght': 21},\n",
       "  '                                                         R3: Average roughness\\n': {'startcol': 57,\n",
       "   'fulllength': 79,\n",
       "   'actuallenght': 21},\n",
       "  '                                                         R4: Smoothness depth\\n': {'startcol': 57,\n",
       "   'fulllength': 78,\n",
       "   'actuallenght': 20},\n",
       "  '                                                         R5: Arithmetic average roughness\\n': {'startcol': 57,\n",
       "   'fulllength': 90,\n",
       "   'actuallenght': 32},\n",
       "  '                                                         R6: Expert\\x19s assessment\\n': {'startcol': 57,\n",
       "   'fulllength': 81,\n",
       "   'actuallenght': 23},\n",
       "  'Illustrative Picture_Code No.11915-K1-12\\n': {'startcol': 0,\n",
       "   'fulllength': 41,\n",
       "   'actuallenght': 40},\n",
       "  '                                                                                                              2% DERMAPEP\" A440\\n': {'startcol': 110,\n",
       "   'fulllength': 128,\n",
       "   'actuallenght': 17},\n",
       "  'T0                              T0+4Weeks\\n': {'startcol': 0,\n",
       "   'fulllength': 42,\n",
       "   'actuallenght': 41},\n",
       "  '                                                                                                     Code                  T+4          T+8       T+12\\n': {'startcol': 101,\n",
       "   'fulllength': 151,\n",
       "   'actuallenght': 49},\n",
       "  '                                                                                                                     T0\\n': {'startcol': 117,\n",
       "   'fulllength': 120,\n",
       "   'actuallenght': 2},\n",
       "  '                                                                                                 11915-K1-12              weeks        weeks      weeks\\n': {'startcol': 97,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 54},\n",
       "  '                                                                                                Skin Roughness      134.2 93.08        99.35      63.18\\n': {'startcol': 96,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 55},\n",
       "  '                                                                                              Maxium Roughness      90.13 66.23        68.86      49.11\\n': {'startcol': 94,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 57},\n",
       "  '                                                                                              Average Roughness      53   48.03         45.6       35.5\\n': {'startcol': 94,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 57},\n",
       "  '                                                                                              Smoothness Depth      62.31 36.36        38.47      26.45\\n': {'startcol': 94,\n",
       "   'fulllength': 152,\n",
       "   'actuallenght': 57},\n",
       "  '                                                                                              Arithmetic average\\n': {'startcol': 94,\n",
       "   'fulllength': 113,\n",
       "   'actuallenght': 18},\n",
       "  '                                                                                                                    31.24 13.62         17.04         9.74\\n': {'startcol': 116,\n",
       "   'fulllength': 155,\n",
       "   'actuallenght': 38},\n",
       "  '                                                                                                  Roughness\\n': {'startcol': 98,\n",
       "   'fulllength': 108,\n",
       "   'actuallenght': 9},\n",
       "  'T0+8Weeks                       T0+16Weeks                                                    Experts assessment      3     3                2          1\\n': {'startcol': 0,\n",
       "   'fulllength': 154,\n",
       "   'actuallenght': 153},\n",
       "  'ÿ                                                  Personal Care Ingredients Business Unit\\n': {'startcol': 0,\n",
       "   'fulllength': 91,\n",
       "   'actuallenght': 90},\n",
       "  '                                                  http://www.dermapep.com E-mail : dermapep@mwc.co.kr\\n': {'startcol': 50,\n",
       "   'fulllength': 102,\n",
       "   'actuallenght': 51},\n",
       "  '                                                                                                      Last revised on Apr 17h, 2013\\n': {'startcol': 102,\n",
       "   'fulllength': 132,\n",
       "   'actuallenght': 29},\n",
       "  'MIWON COMMERCIAL CO., LTD. 405-3 MONGRAE-DONG, DANWON-GU, ANSAN-SHI, GYEONGGI, 425-100, KOREA PHONE +82-31-8084-8410 FAX +82-31-492-2061\\n': {'startcol': 0,\n",
       "   'fulllength': 137,\n",
       "   'actuallenght': 136},\n",
       "  'www.dermapep.com, www.mwc.com\\n': {'startcol': 0,\n",
       "   'fulllength': 30,\n",
       "   'actuallenght': 29}},\n",
       " {'longestsent': 155})"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "getDocProperties(fs1.readlines())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
